CUMULATIVE SUPPLEMENT 2
FEBRUARY 2020



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

40th EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2020

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

40th EDITION

Cumulative Supplement 2
February 2020

CONTENTS

PAGE

Contents

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

40th EDITION

CUMULATIVE SUPPLEMENT 2
FEBRUARY 2020

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AMNEAL PHARMACEUTICALS CO GMBH (AMNEAL PHARMS CO)	AMNEAL EU LTD (AMNEAL EU)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	PHARMACEUTICS INTERNATIONAL INC (PII)

1.4 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP	0.3MG	N021116	RLD	–

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.
[2] Please consult the Active Section of the Orange Book for information on other strengths.

		HOLDINGS 4 LLC				
AB4	LEVOTHYROXINE SODIUM[3]	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

https://www.fda.gov/about-fda/reports-manuals-forms/forms.

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2019	MAR 2020	JUN 2020	SEP 2020	DEC 2020
DRUG PRODUCTS	20567				
LISTED SINGLE SOURCE	2743 (13.3%)				
MULTISOURCE	17824 (86.7%)				

THERAPEUTICALLY EQUIVALENT	17740 (86.3%)
NOT THERAPEUTICALLY EQUIVALENT	84 (0.4%)
EXCEPTIONS[4]	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	17
NUMBER OF APPLICANTS	1162

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN[5]	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).

[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code
CTNA	Change. Trade Name
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

		ACETAMINOPHEN; BUTALBITAL; CAFFEINE						
		TABLET;ORAL						
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
>D>	AA	HIKMA PHARMS	325MG;50MG;40MG		A089718	001	Jun 12, 1995	Feb DISC
>A>		@	325MG;50MG;40MG		A089718	001	Jun 12, 1995	Feb DISC
		ACETAMINOPHEN; HYDROCODONE BITARTRATE						
		TABLET;ORAL						
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
>D>	AA	ACTAVIS LABS FL INC	300MG;5MG		A206470	001	Jun 02, 2016	Feb DISC
>A>		@	300MG;5MG		A206470	001	Jun 02, 2016	Feb DISC
>D>	AA		300MG;7.5MG		A206470	002	Jun 02, 2016	Feb DISC
>A>		@	300MG;7.5MG		A206470	002	Jun 02, 2016	Feb DISC
>D>	AA		300MG;10MG		A206470	003	Jun 02, 2016	Feb DISC
>A>		@	300MG;10MG		A206470	003	Jun 02, 2016	Feb DISC
>D>	AA	XIROMED	325MG;5MG		A211690	001	Feb 07, 2020	Feb CAHN
>A>	AA		325MG;5MG		A211690	001	Feb 07, 2020	Feb CAHN
	AA		325MG;5MG		A211690	001	Feb 07, 2020	Jan NEWA
>D>	AA		325MG;7.5MG		A211690	002	Feb 07, 2020	Feb CAHN
>A>	AA		325MG;7.5MG		A211690	002	Feb 07, 2020	Feb CAHN
	AA		325MG;7.5MG		A211690	002	Feb 07, 2020	Jan NEWA
>D>	AA		325MG;10MG		A211690	003	Feb 07, 2020	Feb CAHN
>A>	AA		325MG;10MG		A211690	003	Feb 07, 2020	Feb CAHN
	AA		325MG;10MG		A211690	003	Feb 07, 2020	Jan NEWA
		ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE						
		SOLUTION;ORAL						
		OXYCODONE AND ACETAMINOPHEN						
>D>		@ MIKART INC	300MG/5ML;10MG/5ML		A202142	001	Nov 27, 2018	Feb CMFD
>A>			300MG/5ML;10MG/5ML		A202142	001	Nov 27, 2018	Feb CMFD
		ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE						
		TABLET;ORAL						
		TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN						
>D>	AB	APOTEX	325MG;37.5MG		A078778	001	Apr 07, 2014	Feb DISC
>A>		@	325MG;37.5MG		A078778	001	Apr 07, 2014	Feb DISC
		ACETAZOLAMIDE SODIUM						
		INJECTABLE;INJECTION						
		ACETAZOLAMIDE SODIUM						
>D>	AP	! X GEN PHARMS	EQ 500MG BASE/VIAL		A040784	001	Dec 10, 2008	Feb CAHN
>A>	AP	! XGEN PHARMS	EQ 500MG BASE/VIAL		A040784	001	Dec 10, 2008	Feb CAHN
		ACYCLOVIR						
		CREAM;TOPICAL						
		ACYCLOVIR						
	AB	! PERRIGO UK FINCO	5%		A208702	001	Feb 04, 2019	Jan CHRS
		ZOVIRAX						
	AB	+ BAUSCH	5%		N021478	001	Dec 30, 2002	Jan CHRS
		OINTMENT;TOPICAL						
		ACYCLOVIR						
	AB	XIROMED	5%		A201501	001	Jan 29, 2020	Jan NEWA
		TABLET;ORAL						
		ACYCLOVIR						
	AB	! HETERO LABS LTD V	800MG		A203834	002	Oct 29, 2013	Jan CHRS
		ZOVIRAX						
		+ @ MYLAN	400MG		N020089	001	Apr 30, 1991	Jan DISC
		+ @	800MG		N020089	002	Apr 30, 1991	Jan DISC
		ALBUTEROL SULFATE						
		AEROSOL, METERED;INHALATION						
>A>		ALBUTEROL SULFATE						
>A>	AB	PERRIGO PHARMS CO	EQ 0.09MG BASE/INH		A203760	001	Feb 24, 2020	Feb NFTG
		PROAIR HFA						
>D>	BX	+! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH		N021457	001	Oct 29, 2004	Feb CFTG
>A>	AB	+!	EQ 0.09MG BASE/INH		N021457	001	Oct 29, 2004	Feb CFTG
		SOLUTION;INHALATION						
		ALBUTEROL SULFATE						
>D>	AN	! BAUSCH AND LOMB	EQ 0.5% BASE		A075050	001	Jun 18, 1998	Feb DISC

		SOLUTION;INHALATION						
		ALBUTEROL SULFATE						
>A>		@	EQ 0.5% BASE	A075050	001	Jun 18, 1998	Feb	DISC
>D>	AN	NEPHRON	EQ 0.5% BASE	A075664	001	Jun 26, 2001	Feb	CHRS
>A>	AN	!	EQ 0.5% BASE	A075664	001	Jun 26, 2001	Feb	CHRS
		ALPRAZOLAM						
		TABLET;ORAL						
		ALPRAZOLAM						
>D>	AB	DAVA INTL INC	0.25MG	A074174	001	Oct 19, 1993	Feb	DISC
>A>		@	0.25MG	A074174	001	Oct 19, 1993	Feb	DISC
>D>	AB		0.5MG	A074174	002	Oct 19, 1993	Feb	DISC
>A>		@	0.5MG	A074174	002	Oct 19, 1993	Feb	DISC
>D>	AB		1MG	A074174	003	Oct 19, 1993	Feb	DISC
>A>		@	1MG	A074174	003	Oct 19, 1993	Feb	DISC
>D>	AB		2MG	A074174	004	Oct 19, 1993	Feb	DISC
>A>		@	2MG	A074174	004	Oct 19, 1993	Feb	DISC
		AMANTADINE HYDROCHLORIDE						
		CAPSULE;ORAL						
		AMANTADINE HYDROCHLORIDE						
>A>	AB	INVATECH	100MG	A210129	001	Mar 02, 2020	Feb	NEWA
		TABLET;ORAL						
		AMANTADINE HYDROCHLORIDE						
>A>	AB	INVATECH	100MG	A210215	001	Mar 10, 2020	Feb	NEWA
		AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL						
		EMULSION;INTRAVENOUS						
		PERIKABIVEN IN PLASTIC CONTAINER						
		+! FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan	CHRS
		AMINOCAPROIC ACID						
		SYRUP;ORAL						
		AMINOCAPROIC ACID						
>A>	AA	VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb	NEWA
		AMIODARONE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		AMIODARONE HYDROCHLORIDE						
>D>	AP	! HOSPIRA	50MG/ML	A075955	001	Oct 18, 2002	Feb	DISC
>A>		@	50MG/ML	A075955	001	Oct 18, 2002	Feb	DISC
>A>		AMISULPRIDE						
>A>		SOLUTION;INTRAVENOUS						
>A>		BARHEMSYS						
>A>		+! ACACIA PHARMA LTD	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020	Feb	NEWA
		AMITRIPTYLINE HYDROCHLORIDE						
		TABLET;ORAL						
		AMITRIPTYLINE HYDROCHLORIDE						
	AB	SANDOZ	10MG	A085968	004		Jan	CMS1
	AB	!	25MG	A085968	002		Jan	CMS1
	AB		75MG	A085968	006		Jan	CMS1
	AB		100MG	A085968	003		Jan	CMS1
	AB		150MG	A085968	005		Jan	CMS1
		AMLODIPINE BESYLATE						
		TABLET;ORAL						
		AMLODIPINE BESYLATE						
>D>	AB	HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Feb	DISC
>A>		@	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Feb	DISC
>D>	AB		EQ 5MG BASE	A077262	002	Jul 09, 2007	Feb	DISC
>A>		@	EQ 5MG BASE	A077262	002	Jul 09, 2007	Feb	DISC
>D>	AB		EQ 10MG BASE	A077262	003	Jul 09, 2007	Feb	DISC
>A>		@	EQ 10MG BASE	A077262	003	Jul 09, 2007	Feb	DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

>D>		@ ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb	CMFD
>D>		@	EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb	CMFD
>A>	AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb	CMFD

AMOXAPINE

TABLET;ORAL

AMOXAPINE

		@ WATSON PHARMS TEVA	25MG	A072418	001	Aug 01, 1989	Jan	CMS1
		@	50MG	A072419	001	Aug 01, 1989	Jan	CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	AB	ANI PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	CAHN
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	CAHN
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	CAHN
	AB		5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	CAHN
	AB		6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	CAHN
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	CAHN
		@ NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019	Jan	DISC
		@	2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019	Jan	DISC
		@	3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019	Jan	DISC
		@	5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019	Jan	DISC
		@	6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019	Jan	DISC
		@	7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019	Jan	DISC

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

	AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan	NEWA
	AA		10MG	A212582	002	Feb 04, 2020	Jan	NEWA
>A>	AA	PRINSTON INC	5MG	A211861	001	Mar 11, 2020	Feb	NEWA
>A>	AA		10MG	A211861	002	Mar 11, 2020	Feb	NEWA

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

>D>	!	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Feb	CAHN
>A>	!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Feb	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

		@ PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Jan	CAHN
		@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Jan	CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

>D>	AB	APOTEX INC	1MG	A200654	001	May 11, 2012	Feb	DISC
>A>		@	1MG	A200654	001	May 11, 2012	Feb	DISC
		@ MYLAN	1MG	A091051	001	Jun 28, 2010	Jan	DISC

APIXABAN

TABLET;ORAL

APIXABAN

		@ MYLAN	2.5MG	A210128	001	Dec 23, 2019	Jan	DISC
		@	5MG	A210128	002	Dec 23, 2019	Jan	DISC

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

SEPTOCAINE

>D>	AP	+! DEPROCO	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000	Feb	CTEC
>A>		+!	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000	Feb	CTEC
>D>		ULTACAN FORTE						
>D>	AP	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Feb	DISC
>A>		@	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Feb	DISC

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

		+ ALLERGAN	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Jan	CMS1

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

>D>	AB	MYLAN	EQ 150MG BASE	A208177	001	Sep 24, 2018	Feb	DISC
>A>		@	EQ 150MG BASE	A208177	001	Sep 24, 2018	Feb	DISC
>D>	AB		EQ 200MG BASE	A208177	002	Sep 24, 2018	Feb	DISC
>A>		@	EQ 200MG BASE	A208177	002	Sep 24, 2018	Feb	DISC
>D>	AB		EQ 300MG BASE	A208177	003	Sep 24, 2018	Feb	DISC
>A>		@	EQ 300MG BASE	A208177	003	Sep 24, 2018	Feb	DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

	AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Jan	CMFD
	AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jan	CMFD
	AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jan	CMFD
	AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jan	CMFD

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

>D>		ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Feb	CHRS
>A>		!	1%	N208151	001	Dec 01, 2016	Feb	CHRS
>A>		!+	1%	N208151	001	Dec 01, 2016	Feb	CRLD

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>A>	AA	LEADING PHARMA LLC	0.025MG;2.5MG	A213413	001	Feb 20, 2020	Feb	NEWA

AVAPRITINIB

TABLET;ORAL

AYVAKIT

		+ BLUEPRINT MEDICINES	100MG	N212608	001	Jan 09, 2020	Jan	NEWA
		+	200MG	N212608	002	Jan 09, 2020	Jan	NEWA
		+!	300MG	N212608	003	Jan 09, 2020	Jan	NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

>A>	AT		GLAND PHARMA LTD	0.05%	A210092	001	Feb 25, 2020	Feb NEWA

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

	AB		ALEMBIC PHARMS LTD	EQ 250MG BASE	A211791	001	Jan 28, 2020	Jan NEWA
	AB			EQ 500MG BASE	A211792	001	Jan 28, 2020	Jan NEWA
	AB			EQ 600MG BASE	A211793	001	Jan 27, 2020	Jan NEWA
		@	MYLAN	EQ 600MG BASE	A065360	001	Jan 08, 2007	Jan DISC

BACLOFEN

TABLET;ORAL

BACLOFEN

		@	MYLAN	20MG	A077121	002	Jul 29, 2005	Jan DISC

>A> BEMPEDOIC ACID

>A> TABLET;ORAL

>A> NEXLETOL

>A>		+!	ESPERION THERAPS INC	180MG	N211616	001	Feb 21, 2020	Feb NEWA

>A> BEMPEDOIC ACID; EZETIMIBE

>A> TABLET;ORAL

>A> NEXLIZET

>A>		+!	ESPERION THERAPS INC	180MG;10MG	N211617	001	Feb 26, 2020	Feb NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

>D>	AB		APOTEX	5MG	A077128	001	Mar 08, 2006	Feb CAHN
>D>	AB			10MG	A077128	002	Mar 08, 2006	Feb CAHN
>D>	AB			20MG	A077128	003	Mar 08, 2006	Feb CAHN
>D>	AB			40MG	A077128	004	Mar 08, 2006	Feb CAHN
>A>	AB		COREPHARMA	5MG	A077128	001	Mar 08, 2006	Feb CAHN
>A>	AB			10MG	A077128	002	Mar 08, 2006	Feb CAHN
>A>	AB			20MG	A077128	003	Mar 08, 2006	Feb CAHN
>A>	AB			40MG	A077128	004	Mar 08, 2006	Feb CAHN

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

>D> BEPOTASTINE BESILATE

>D>	AT		MYLAN	1.5%	A206220	001	Mar 18, 2019	Feb DISC
>A>		@		1.5%	A206220	001	Mar 18, 2019	Feb DISC

BEPREVE

>D>	AT	+!	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb CTEC
>A>		+!		1.5%	N022288	001	Sep 08, 2009	Feb CTEC

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

>D>	AB		GLENMARK GENERICS	EQ 0.05% BASE	A078930	001	Sep 23, 2008	Feb CHRS
>A>	AB	!		EQ 0.05% BASE	A078930	001	Sep 23, 2008	Feb CHRS

>D> DIPROLENE AF

>D>	AB	+!	MERCK SHARP DOHME	EQ 0.05% BASE	N019555	001	Apr 27, 1987	Feb DISC
>A>		+ @		EQ 0.05% BASE	N019555	001	Apr 27, 1987	Feb DISC

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

	AA	!	AMNEAL PHARM	5MG	A040855	001	Nov 21, 2007	Jan CHRS
	AA	!		10MG	A040855	002	Nov 21, 2007	Jan CHRS
	AA	!		25MG	A040855	003	Nov 21, 2007	Jan CHRS
		@	IMPAX LABS	25MG	A040721	003	Nov 01, 2006	Jan CMS1

URECHOLINE

		@	ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985	Jan DISC
		@		10MG	A088440	001	May 29, 1984	Jan DISC
		@		25MG	A088441	001	May 29, 1984	Jan DISC

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB	ANI PHARMS INC	75MG	A209861	001	May 08, 2018	Jan	CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

@	MYLAN	50MG	A079185	001	Jul 06, 2009	Jan	DISC

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT	ALEMBIC PHARMS LTD	0.03%	A210515	001	Jan 21, 2020	Jan	NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

>D>	AP	APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017	Feb	DISC
>A>	@		250MG/VIAL	A204876	001	Jul 06, 2017	Feb	DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

AB		ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan	NEWA
AB			125MG	A211461	002	Jan 23, 2020	Jan	NEWA
	@	MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan	DISC
	@		125MG	A205173	002	Jan 15, 2020	Jan	DISC

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

>A>	+!	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Feb	CAHN
>D>	+!	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Feb	CAHN

BUMETANIDE

TABLET;ORAL

BUMETANIDE

AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Jan	CAHN
AB		1MG	A212019	002	Dec 12, 2019	Jan	CAHN
AB		2MG	A212019	003	Dec 12, 2019	Jan	CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB		CADILA PHARMS LTD	75MG	A208606	001	Jan 16, 2020	Jan	NEWA
AB			100MG	A208606	002	Jan 16, 2020	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

>D>	AB1	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Feb	DISC
>A>	@		100MG	A202774	001	Oct 11, 2013	Feb	DISC
>D>	AB1		150MG	A202774	002	Oct 11, 2013	Feb	DISC
>A>	@		150MG	A202774	002	Oct 11, 2013	Feb	DISC
>D>	AB2		150MG	A202775	001	Oct 11, 2013	Feb	DISC
>A>	@		150MG	A202775	001	Oct 11, 2013	Feb	DISC
>D>	AB3		150MG	A207459	001	Jun 30, 2017	Feb	DISC
>A>	@		150MG	A207459	001	Jun 30, 2017	Feb	DISC
>D>	AB1		200MG	A202774	003	Oct 11, 2013	Feb	DISC
>A>	@		200MG	A202774	003	Oct 11, 2013	Feb	DISC
>D>	AB3		300MG	A207459	002	Jun 30, 2017	Feb	DISC
>A>	@		300MG	A207459	002	Jun 30, 2017	Feb	DISC

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

	+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014	Jan	CAHN

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

>D>	AP		MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Feb DISC
>A>		@		6MG/ML	A205184	001	Jul 13, 2018	Feb DISC

CABERGOLINE

TABLET;ORAL

CABERGOLINE

		@	MYLAN	0.5MG	A202947	001	Dec 02, 2013	Jan DISC

CALCITRIOL

INJECTABLE;INJECTION

CALCITRIOL

	AP	!	AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Jan CTEC
	AP		GLAND PHARMA LTD	0.001MG/ML	A211030	001	Feb 03, 2020	Jan NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

		@	LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jan DISC
>A>	AB		SUVEN LIFE	667MG	A211038	001	Feb 21, 2020	Feb NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

>D>		@	APOTEX	12.5MG	A074737	001	Oct 28, 1998	Feb CAHN
>D>		@		25MG	A074737	002	Oct 28, 1998	Feb CAHN
>D>		@		50MG	A074737	003	Oct 28, 1998	Feb CAHN
>D>		@		100MG	A074737	004	Oct 28, 1998	Feb CAHN
>A>		@	COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Feb CAHN
>A>		@		25MG	A074737	002	Oct 28, 1998	Feb CAHN
>A>		@		50MG	A074737	003	Oct 28, 1998	Feb CAHN
>A>		@		100MG	A074737	004	Oct 28, 1998	Feb CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

	AB		ANI PHARMS INC	25MG	A203261	001	Mar 10, 2014	Jan CAHN

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

SINEMET CR

		+ @	MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan DISC

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

>D>	AA		HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Feb DISC
>A>		@		350MG	A040124	001	Jan 24, 1996	Feb DISC

CEFIXIME

FOR SUSPENSION;ORAL

SUPRAX

		@	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Jan DISC

TABLET;ORAL

SUPRAX

		@	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004	Jan DISC

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

		@	HOSPIRA INC	EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

>A>	AB		TIANJIN TIANYAO	50MG	A207872	001	Feb 25, 2020	Feb NEWA
>A>	AB			100MG	A207872	002	Feb 25, 2020	Feb NEWA
>A>	AB			200MG	A207872	003	Feb 25, 2020	Feb NEWA
>A>	AB			400MG	A207872	004	Feb 25, 2020	Feb NEWA

CAPSULE;ORAL
CELECOXIB

	AB	UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan CDFR
	AB		100MG	A210628	002	Nov 27, 2019	Jan CDFR
	AB		200MG	A210628	003	Nov 27, 2019	Jan CDFR
	AB		400MG	A210628	004	Nov 27, 2019	Jan CDFR
>A>	AB	YILING PHARM LTD	50MG	A211412	001	Mar 06, 2020	Feb NEWA
>A>	AB		100MG	A211412	002	Mar 06, 2020	Feb NEWA
>A>	AB		200MG	A211412	003	Mar 06, 2020	Feb NEWA
>A>	AB		400MG	A211412	004	Mar 06, 2020	Feb NEWA

CHLOROQUINE PHOSPHATE
TABLET;ORAL
CHLOROQUINE PHOSPHATE

>D>	AA	! HIKMA PHARMS	EQ 150MG BASE	A083082	001		Feb DISC
>A>		@	EQ 150MG BASE	A083082	001		Feb DISC
>D>	AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Feb CHRS
>A>	AA	!	EQ 150MG BASE	A091621	001	Jan 21, 2011	Feb CHRS

CHLORPROMAZINE HYDROCHLORIDE
TABLET;ORAL
CHLORPROMAZINE HYDROCHLORIDE

	AB	ZYDUS	10MG	A213368	001	Jan 17, 2020	Jan NEWA
	AB		25MG	A213368	002	Jan 17, 2020	Jan NEWA
	AB		50MG	A213368	003	Jan 17, 2020	Jan NEWA
	AB		100MG	A213368	004	Jan 17, 2020	Jan NEWA
	AB		200MG	A213368	005	Jan 17, 2020	Jan NEWA

CHLORTHALIDONE
TABLET;ORAL
CHLORTHALIDONE

	AB	ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020	Jan NEWA
	AB		50MG	A213412	002	Feb 11, 2020	Jan NEWA
>D>	AB	ATHEM	25MG	A211063	001	Feb 26, 2019	Feb CAHN
>D>	AB		50MG	A211063	002	Feb 26, 2019	Feb CAHN
>A>	AB	VISTAPHARM	25MG	A211063	001	Feb 26, 2019	Feb CAHN
>A>	AB		50MG	A211063	002	Feb 26, 2019	Feb CAHN

CHOLESTYRAMINE
POWDER;ORAL
LOCHOLEST

>A>		@ ALLIED	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Feb CAHN
>A>		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Feb CAHN
>D>		@ INVATECH	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Feb CAHN
		@	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Jan CAHN
>D>		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Feb CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Jan CAHN

LOCHOLEST LIGHT

>A>		@ ALLIED	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Feb CAHN
>A>		@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Feb CAHN
>D>		@ INVATECH	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Feb CAHN
>D>		@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Feb CAHN

CINACALCET HYDROCHLORIDE
TABLET;ORAL
CINACALCET HYDROCHLORIDE

		@ LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan DISC
		@	EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan DISC
		@	EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan DISC

CISATRACURIUM BESYLATE
INJECTABLE;INJECTION
CISATRACURIUM BESYLATE

	AP	HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan CMFD

CLINDAMYCIN PHOSPHATE
AEROSOL, FOAM;TOPICAL
CLINDAMYCIN PHOSPHATE

>A>	AT	TARO PHARM INDS LTD	1%	A210004	001	Mar 11, 2020	Feb NEWA

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

>A>	AB	HETERO LABS LTD III	2.5MG/ML	A209796	001	Feb 24, 2020	Feb NEWA
	AB	TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020	Jan NEWA

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

	AB1	ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan NEWA

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

		@ ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Jan DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

	AB	LEADING PHARMA LLC	25MG	A211364	001	Feb 07, 2020	Jan NEWA
	AB		50MG	A211364	002	Feb 07, 2020	Jan NEWA
	AB		75MG	A211364	003	Feb 07, 2020	Jan NEWA
	AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Jan CMFD
	AB		50MG	A211767	002	Apr 08, 2019	Jan CMFD
	AB		75MG	A211767	003	Apr 08, 2019	Jan CMFD
>D>	AB	TEVA	25MG	A074958	001	Aug 26, 1997	Feb DISC
>A>		@	25MG	A074958	001	Aug 26, 1997	Feb DISC
>D>	AB		50MG	A074958	002	Aug 26, 1997	Feb DISC
>A>		@	50MG	A074958	002	Aug 26, 1997	Feb DISC
>D>	AB		75MG	A074958	003	Aug 26, 1997	Feb DISC
>A>		@	75MG	A074958	003	Aug 26, 1997	Feb DISC

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

>D>	AP	X-GEN PHARMS INC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Feb CAHN
>D>	AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Feb CAHN
>A>	AP	XGEN PHARMS	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Feb CAHN
>A>	AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

>D>		@ UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	Feb CMFD
>A>	AB1		0.1MG	A211433	001	Oct 12, 2018	Feb CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

>D>		@ AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 11, 2017	Feb CMS1
>A>		@	3.75MG	A072112	002	Aug 26, 1988	Feb CMS1
>D>		@	7.5MG	A072112	003	Aug 11, 2017	Feb CMS1
>A>		@	7.5MG	A072112	003	Aug 26, 1988	Feb CMS1

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

NUMBRINO

		CODY LABS INC	4%	N209575	001	Jan 10, 2020	Jan NEWA

COLCHICINE

TABLET;ORAL

COLCHICINE

	AB	AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Jan CMFD
	AB	GRANULES PHARMS	0.6MG	A210425	001	Feb 05, 2020	Jan NEWA

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

>D>	AP	X GEN PHARMS	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Feb CAHN
>A>	AP	XGEN PHARMS	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Feb CAHN

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

	AB		ANI PHARMS INC	25MG	A207014	001	Mar 19, 2018	Jan CAHN
	AB			50MG	A207014	002	Mar 19, 2018	Jan CAHN

CYSTEAMINE BITARTRATE

GRANULE;ORAL

PROCYSBI

>A>		+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Feb NEWA
>A>		+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Feb NEWA

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

>A> DABIGATRAN ETEXILATE MESYLATE

>A>	AB		ALKEM LABS LTD	EQ 75MG BASE	A208040	001	Mar 11, 2020	Feb NFTG
>A>	AB			EQ 150MG BASE	A208040	002	Mar 11, 2020	Feb NFTG

PRADAXA

>D>		+	BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010	Feb CFTG
>A>	AB	+		EQ 75MG BASE	N022512	001	Oct 19, 2010	Feb CFTG
>D>		+!		EQ 150MG BASE	N022512	002	Oct 19, 2010	Feb CFTG
>A>	AB	+!		EQ 150MG BASE	N022512	002	Oct 19, 2010	Feb CFTG

DACTINOMYCIN

INJECTABLE;INJECTION

DACTINOMYCIN

>D>	AP		X-GEN PHARMS INC	0.5MG/VIAL	A203999	001	May 20, 2019	Feb CAHN
>A>	AP		XGEN PHARMS	0.5MG/VIAL	A203999	001	May 20, 2019	Feb CAHN

DAPSONE

GEL;TOPICAL

DAPSONE

>A>	AB		TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Feb NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

>D>	AB		ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Feb DISC
>A>		@		EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Feb DISC
>D>	AB			EQ 15MG BASE	A091190	002	Mar 13, 2015	Feb DISC
>A>		@		EQ 15MG BASE	A091190	002	Mar 13, 2015	Feb DISC

DEFERASIROX

TABLET;ORAL

DEFERASIROX

>A>	AB		AMNEAL	90MG	A210727	001	Dec 27, 2019	Feb CAHN
>A>	AB			360MG	A210727	002	Dec 27, 2019	Feb CAHN
>D>	AB		AMNEAL PHARMS CO	90MG	A210727	001	Dec 27, 2019	Feb CAHN
>D>	AB			360MG	A210727	002	Dec 27, 2019	Feb CAHN
	AB		CIPLA	90MG	A211852	001	Feb 11, 2020	Jan NEWA
	AB			360MG	A211852	002	Feb 11, 2020	Jan NEWA

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS

IPRIVASK

		+ @	BAUSCH	15MG/VIAL	N021271	001	Apr 04, 2003	Jan CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DESMOPRESSIN ACETATE

>A>	AP		UBI	0.004MG/ML	A210218	001	Feb 14, 2020	Feb NEWA

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

>A>	AB		COSETTE	0.25%	A209595	001	Mar 04, 2020	Feb NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

>D>	AB		MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Feb DISC
>A>		@		EQ 50MG BASE	A204095	001	Jun 29, 2015	Feb DISC

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX ST

>A>		+!	EYEVANCE	0.05%;0.3%	N050818	001	Feb 13, 2009	Feb CAHN
>D>		+!	NOVARTIS	0.05%;0.3%	N050818	001	Feb 13, 2009	Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE

	AP		JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan CTNA

DEXMEDETOMIDINE HYDROCHLORIDE

	AP		HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan NEWA
	AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

		@	PII	5MG	A205077	001	Jun 21, 2019	Jan DISC
		@		10MG	A205077	002	Jun 21, 2019	Jan DISC
		@		15MG	A205077	003	Jun 21, 2019	Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

>A>		@	SLATE	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Feb CAHN
>D>		@	VINTAGE	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Feb CAHN

DIAZEPAM

SPRAY;NASAL

VALTOCO

		+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan NEWA
		+		7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan NEWA
		+!		10MG/SPRAY	N211635	003	Jan 10, 2020	Jan NEWA

DICLOFENAC EPOLAMINE

>D> PATCH;TOPICAL

>D> FLECTOR

>D>		+!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	Feb CDFR

>A> SYSTEM;TOPICAL

>A> FLECTOR

>A>		+!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	Feb CDFR

DICLOFENAC POTASSIUM

TABLET;ORAL

CATAFLAM

		+ @	NOVARTIS	50MG	N020142	002	Nov 24, 1993	Jan CRLD

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

	AB		ENCUBE	1%	A210986	001	Jan 27, 2020	Jan NEWA

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

>A>	AB		YUNG SHIN PHARM	50MG;0.2MG	A205143	001	Feb 19, 2020	Feb NEWA
>A>	AB			75MG;0.2MG	A205143	002	Feb 19, 2020	Feb NEWA

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL

>A>		DIHYDROERGOTAMINE MESYLATE						
>A>	AB	CUSTOPHARM INC	0.5MG/SPRAY	A211393	001	Feb 28, 2020	Feb	NFTG
		MIGRANAL						
>D>	+!	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Feb	CFTG
>A>	AB +!		0.5MG/SPRAY	N020148	001	Dec 08, 1997	Feb	CFTG

DISULFIRAM

TABLET;ORAL

		DISULFIRAM						
>D>	AB	HIKMA	250MG	A202652	001	Feb 05, 2014	Feb	DISC
>A>		@	250MG	A202652	001	Feb 05, 2014	Feb	DISC
>D>	AB		500MG	A202652	002	Feb 05, 2014	Feb	DISC
>A>		@	500MG	A202652	002	Feb 05, 2014	Feb	DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

		DIVALPROEX SODIUM						
>A>	AB	AJANTA PHARMA LTD	EQ 125MG VALPROIC ACID	A213181	001	Mar 02, 2020	Feb	NEWA
		@ MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Jan	DISC

TABLET, DELAYED RELEASE;ORAL

		DIVALPROEX SODIUM						
		@ MYLAN	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jan	DISC
		@	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jan	DISC
		@	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jan	DISC

DOCETAXEL

INJECTABLE;INJECTION

		DOCETAXEL						
	AP	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Jan	CMFD
	AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Jan	CMFD
	AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Jan	CMFD

DOFETILIDE

CAPSULE;ORAL

		DOFETILIDE						
	AB	MSN	0.125MG	A213220	001	Jan 29, 2020	Jan	NEWA
	AB		0.25MG	A213220	002	Jan 29, 2020	Jan	NEWA
	AB		0.5MG	A213220	003	Jan 29, 2020	Jan	NEWA

DOXAZOSIN MESYLATE

TABLET;ORAL

		DOXAZOSIN MESYLATE						
		@ ANI PHARMS INC	EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan	DISC
		@	EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan	DISC
		@	EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan	DISC
		@	EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan	DISC

DOXERCALCIFEROL

INJECTABLE;INJECTION

		DOXERCALCIFEROL						
>A>	AP	MEITHEAL	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Feb	CAHN
>D>	AP	NANJING KING-FRIEND	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Feb	CAHN
	AP		4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Jan	NEWA

DOXYCYCLINE

CAPSULE;ORAL

		DOXYCYCLINE						
		@ MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	Jan	DISC

DOXYCYCLINE HYCLATE

TABLET;ORAL

		DOXYCYCLINE HYCLATE						
>A>	AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A210537	001	Mar 03, 2020	Feb	NEWA

TABLET, DELAYED RELEASE;ORAL

		DOXYCYCLINE HYCLATE						
>A>	AB	PRINSTON INC	EQ 50MG BASE	A207494	003	Feb 19, 2019	Feb	NEWA

DRONABINOL

CAPSULE;ORAL

DRONABINOL

	AB		ASCENT PHARMS INC	2.5MG	A207421	001	Feb 07, 2020	Jan NEWA
	AB			5MG	A207421	002	Feb 07, 2020	Jan NEWA
	AB			10MG	A207421	003	Feb 07, 2020	Jan NEWA

MARINOL

	AB	+	ALKEM LABS LTD	2.5MG	N018651	001	May 31, 1985	Jan CAHN
	AB	+!		5MG	N018651	002	May 31, 1985	Jan CAHN
	AB	+		10MG	N018651	003	May 31, 1985	Jan CAHN

SOLUTION;ORAL

SYNDROS

>A>		+!	BENUVIA	5MG/ML	N205525	001	Mar 23, 2017	Feb CAHN
>D>		+!	INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017	Feb CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

	AB		ALLIED	3MG;0.02MG	A203291	001	Jul 18, 2017	Jan CAHN

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

	AB		HETERO LABS LTD	3MG;0.03MG	A213034	001	Jan 24, 2020	Jan NEWA

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

		@	ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Jan DISC
>D>	AB		APOTEX INC	0.5MG	A204292	001	Nov 24, 2015	Feb DISC
>A>		@		0.5MG	A204292	001	Nov 24, 2015	Feb DISC
>D>	AB		HIKMA	0.5MG	A202204	001	Nov 23, 2015	Feb DISC
>A>		@		0.5MG	A202204	001	Nov 23, 2015	Feb DISC

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRIJARDY XR

		+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020	Jan NEWA
		+		10MG;5MG;1GM	N212614	002	Jan 27, 2020	Jan NEWA
		+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020	Jan NEWA
		+!		25MG;5MG;1GM	N212614	004	Jan 27, 2020	Jan NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>D>	AB		MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb DISC
>A>		@		200MG;300MG	A206436	001	Apr 09, 2018	Feb DISC
>A>	AB		ZYDUS PHARMS	200MG;300MG	A212689	001	Feb 28, 2020	Feb NEWA

ENTECAVIR

TABLET;ORAL

ENTECAVIR

		@	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Jan DISC
		@		1MG	A206226	002	Mar 26, 2019	Jan DISC

EPLERENONE

TABLET;ORAL

EPLERENONE

>D>	AB		APOTEX	25MG	A078482	001	Jul 30, 2008	Feb CAHN
>D>	AB			50MG	A078482	002	Jul 30, 2008	Feb CAHN
>A>	AB		COREPHARMA	25MG	A078482	001	Jul 30, 2008	Feb CAHN
>A>	AB			50MG	A078482	002	Jul 30, 2008	Feb CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

	AA		ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan CAHN

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

>A>	AB		DR REDDYS LABS LTD	EQ 20MG BASE;375MG	A204206	001	Feb 18, 2020	Feb NEWA
>A>	AB			EQ 20MG BASE;500MG	A204206	002	Feb 18, 2020	Feb NEWA

VIMOVO

>D>		+	HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Feb CTEC
>A>	AB	+		EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Feb CTEC
>D>		+!		EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Feb CTEC
>A>	AB	+!		EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Feb CTEC

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

			@ TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Jan DISC

ESTROPIPATE

TABLET;ORAL

ESTROPIPATE

			@ MYLAN	0.75MG	A040359	001	Aug 26, 1999	Jan DISC
			@	1.5MG	A040359	002	Aug 26, 1999	Jan DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

>D>	AB		HIKMA	1MG	A091153	001	Apr 15, 2014	Feb DISC
>A>			@	1MG	A091153	001	Apr 15, 2014	Feb DISC
>D>	AB			2MG	A091153	002	Apr 15, 2014	Feb DISC
>A>			@	2MG	A091153	002	Apr 15, 2014	Feb DISC
>D>	AB			3MG	A091153	003	Apr 15, 2014	Feb DISC
>A>			@	3MG	A091153	003	Apr 15, 2014	Feb DISC

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

>A>	AB		UPSHER SMITH LABS	25MG	A212417	001	Feb 19, 2020	Feb NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

>A>			SYSTEM;TRANSDERMAL					
>A>			TWIRLA					
>A>		+!	AGILE	0.03MG/24HR;0.12MG/24HR	N204017	001	Feb 14, 2020	Feb NEWA

TABLET;ORAL

BALCOLTRA

		+!	AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan CHRS
		+		0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan CRLD

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D>	AB		MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	Feb DISC
>A>			@	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	Feb DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

LOESTRIN 24 FE

	AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N021871	001	Feb 17, 2006	Jan CAHN

TABLET;ORAL-21

LOESTRIN 21 1.5/30

	AB	+	TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jan CAHN

LOESTRIN 21 1/20

	AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N017876	001		Jan CAHN

LOESTRIN FE 1.5/30

	AB	+!	TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001		Jan CAHN

TABLET;ORAL-28

LOESTRIN FE 1/20

	AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N017354	001		Jan CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

>D>	AB		MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb DISC
>A>			@	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb DISC

ETODOLAC

TABLET;ORAL

ETODOLAC

>D>	AB		TEVA	400MG	A075009	001	Nov 26, 1997	Feb DISC
>A>		@		400MG	A075009	001	Nov 26, 1997	Feb DISC
>D>	AB			500MG	A075009	002	Dec 28, 1999	Feb DISC
>A>		@		500MG	A075009	002	Dec 28, 1999	Feb DISC

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

>D>	AP		MYLAN LABS LTD	2MG/ML	A078289	001	Jan 02, 2009	Feb DISC
>A>		@		2MG/ML	A078289	001	Jan 02, 2009	Feb DISC

EXEMESTANE

TABLET;ORAL

EXEMESTANE

		@	MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019	Jan DISC

EZETIMIBE

TABLET;ORAL

EZETIMIBE

>D>	AB		MYLAN	10MG	A201790	001	Apr 26, 2019	Feb DISC
>A>		@		10MG	A201790	001	Apr 26, 2019	Feb DISC

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	AB	!	AUROBINDO PHARMA LTD	40MG	A206530	002	Dec 22, 2015	Jan CHRS
>D>	AB		MYLAN	20MG	A075704	001	Apr 16, 2001	Feb DISC
>A>		@		20MG	A075704	001	Apr 16, 2001	Feb DISC

PEPCID

	+	@	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Jan DISC
	+	@		40MG	N019462	002	Oct 15, 1986	Jan DISC

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

	AB		ANI PHARMS INC	67MG	A209504	001	Apr 30, 2018	Jan CAHN
	AB			134MG	A209504	002	Apr 30, 2018	Jan CAHN
	AB			200MG	A209504	003	Apr 30, 2018	Jan CAHN

TABLET;ORAL

FENOFIBRATE

	AB		ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan NEWA
	AB			160MG	A213252	002	Jan 17, 2020	Jan NEWA
	AB		APPCO	54MG	A210670	001	Sep 06, 2019	Jan CAHN
	AB			160MG	A210670	002	Sep 06, 2019	Jan CAHN
	AB		GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Jan CMFD
	AB			160MG	A210606	002	Aug 17, 2018	Jan CMFD

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

>A>	AP	+!	HIKMA	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
>D>	AP	+!	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN

FERRIC DERISOMALTOSE

SOLUTION;INTRAVENOUS

MONOFERRIC

		+!	PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020	Jan NEWA
		+!		500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020	Jan NEWA
		+!		1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020	Jan NEWA

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

>D>	AB		DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Feb DISC
>A>		@		4MG	A204975	001	Aug 13, 2019	Feb DISC
>D>	AB			8MG	A204975	002	Aug 13, 2019	Feb DISC
>A>		@		8MG	A204975	002	Aug 13, 2019	Feb DISC

FIDAXOMICIN

FOR SUSPENSION;ORAL

DIFICID

		+!	CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020 Jan NEWA

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

>D>	AB		HIKMA	50MG/5ML	A076246	001	Jul 29, 2004 Feb DISC
>A>		@		50MG/5ML	A076246	001	Jul 29, 2004 Feb DISC
>D>	AB			200MG/5ML	A076246	002	Jul 29, 2004 Feb DISC
>A>		@		200MG/5ML	A076246	002	Jul 29, 2004 Feb DISC

TABLET;ORAL

FLUCONAZOLE

		@	MYLAN	50MG	A076351	001	Jul 29, 2004 Jan DISC
		@		100MG	A076351	002	Jul 29, 2004 Jan DISC
		@		150MG	A076351	003	Jul 29, 2004 Jan DISC
		@		200MG	A076351	004	Jul 29, 2004 Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

	AP		UNIV TX SW MEDCTR	20-200mCi/ML	A210265	001	Feb 06, 2020 Jan NEWA

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

>A>	AB		CADILA	0.1%	A208989	001	Feb 10, 2020 Feb CAHN
>D>	AB		ZYDUS PHARMS	0.1%	A208989	001	Feb 10, 2020 Feb CAHN
	AB			0.1%	A208989	001	Feb 10, 2020 Jan NEWA

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

>D>	AP		X-GEN PHARMS INC	5MG/ML	A202522	001	Nov 06, 2019 Feb CAHN
	AP			5MG/ML	A202522	001	Nov 06, 2019 Jan CAHN
>A>	AP		XGEN PHARMS	5MG/ML	A202522	001	Nov 06, 2019 Feb CAHN

FULVESTRANT

INJECTABLE;INTRAMUSCULAR

FULVESTRANT

	AO		CHIA TAI TIANQING	50MG/ML	A211422	001	Feb 07, 2020 Jan NEWA

FUROSEMIDE

TABLET;ORAL

FUROSEMIDE

		@	AVET	20MG	N018413	001	Nov 30, 1983 Jan DISC
		@		40MG	N018413	002	Nov 30, 1983 Jan DISC

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

	AB		CSPC OUYI	100MG	A075477	001	Mar 23, 2005 Jan CMFD
	AB			300MG	A075477	002	Mar 23, 2005 Jan CMFD
	AB			400MG	A075477	003	Mar 23, 2005 Jan CMFD

TABLET;ORAL

GRALISE

	BX	+!	ALMATICA	300MG	N022544	001	Jan 28, 2011 Jan CAHN
	BX	+!		600MG	N022544	002	Jan 28, 2011 Jan CAHN

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB		HIKMA	EQ 4MG BASE	A077608	001	Feb 11, 2009 Feb DISC
>A>		@		EQ 4MG BASE	A077608	001	Feb 11, 2009 Feb DISC
>D>	AB			EQ 8MG BASE	A077608	002	Feb 11, 2009 Feb DISC
>A>		@		EQ 8MG BASE	A077608	002	Feb 11, 2009 Feb DISC
>D>	AB			EQ 12MG BASE	A077608	003	Feb 11, 2009 Feb DISC
>A>		@		EQ 12MG BASE	A077608	003	Feb 11, 2009 Feb DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

>D>	AP		APOTEX	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	Feb DISC
>A>		@		200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	Feb DISC
>D>	AP			1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	Feb DISC
>A>		@		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	Feb DISC
>D>	AP			2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	Feb DISC
>A>		@		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	Feb DISC
	AP		SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Jan CMFD
	AP			EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Jan CMFD

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

>A>	AB		CADILA	600MG	A204189	001	Aug 28, 2018	Feb CAHN
>D>	AB		TEVA	600MG	A074256	001	Oct 31, 1993	Feb DISC
>A>		@		600MG	A074256	001	Oct 31, 1993	Feb DISC
>D>	AB		ZYDUS PHARMS	600MG	A204189	001	Aug 28, 2018	Feb CAHN

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

		@	MYLAN	1.5MG	A074792	001	Jun 26, 1998	Jan DISC
		@		3MG	A074792	002	Jun 26, 1998	Jan DISC
		@		6MG	A074792	003	Aug 17, 1999	Jan DISC

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

>A>	AP		RICONPHARMA LLC	0.2MG/ML	A210083	001	Feb 21, 2020	Feb NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP		YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Feb NEWA

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

		@	MYLAN	EQ 1MG BASE	A078725	001	Jan 30, 2008	Jan DISC

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

>A>	AP		NANJING KING-FRIEND	20,000 UNITS/ML	A211004	001	Feb 24, 2020	Feb NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

	AA	!	NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011	Jan CHRS

TUSSIGON

		@	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Jan DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

>D>	AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Feb CAHN
>A>	AP		XGEN PHARMS	20MG/ML	A203110	001	Jun 29, 2015	Feb CAHN

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

		@	STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019	Jan DISC

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

		@	MYLAN PHARMS INC	25MG	A040735	002	Jan 23, 2007	Jan DISC
		@		50MG	A040735	003	Jan 23, 2007	Jan DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

>D>		@ APOTEX	12.5MG;10MG	A076674	001	Oct 05, 2004	Feb	CAHN
>D>		@	12.5MG;20MG	A076674	002	Oct 05, 2004	Feb	CAHN
>D>		@	25MG;20MG	A076674	003	Oct 05, 2004	Feb	CAHN
>A>		@ COREPHARMA	12.5MG;10MG	A076674	001	Oct 05, 2004	Feb	CAHN
>A>		@	12.5MG;20MG	A076674	002	Oct 05, 2004	Feb	CAHN
>A>		@	25MG;20MG	A076674	003	Oct 05, 2004	Feb	CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A>	AB	CADILA	25MG;37.5MG	A208358	001	Feb 11, 2019	Feb	CAHN
>D>	AB	ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11, 2019	Feb	CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

	AB	ALVOGEN	10MG	A206986	001	Jan 21, 2020	Jan	NFTG
	AB		15MG	A206986	002	Jan 21, 2020	Jan	NFTG
	AB		20MG	A206986	003	Jan 21, 2020	Jan	NFTG
	AB		30MG	A206986	004	Jan 21, 2020	Jan	NFTG
	AB		40MG	A206986	005	Jan 21, 2020	Jan	NFTG
	AB		50MG	A206986	006	Jan 21, 2020	Jan	NFTG

ZOHYDRO ER

	AB	+! PERSION	10MG	N202880	001	Oct 25, 2013	Jan	CFTG
	AB	+	15MG	N202880	002	Oct 25, 2013	Jan	CFTG
	AB	+	20MG	N202880	003	Oct 25, 2013	Jan	CFTG
	AB	+	30MG	N202880	004	Oct 25, 2013	Jan	CFTG
	AB	+	40MG	N202880	005	Oct 25, 2013	Jan	CFTG
	AB	+	50MG	N202880	006	Oct 25, 2013	Jan	CFTG

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

>D>	AB	PII	5MG	A207029	001	Apr 27, 2017	Feb	CAHN
>D>	AB		10MG	A207029	002	Apr 27, 2017	Feb	CAHN
>D>	AB		20MG	A207029	003	Apr 27, 2017	Feb	CAHN
>A>	AB	STRIDES PHARMA	5MG	A207029	001	Apr 27, 2017	Feb	CAHN
>A>	AB		10MG	A207029	002	Apr 27, 2017	Feb	CAHN
>A>	AB		20MG	A207029	003	Apr 27, 2017	Feb	CAHN

HYDROCORTISONE VALERATE

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

>A>	AB	COSETTE	0.2%	A211764	001	Mar 04, 2020	Feb	NEWA

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

		+! FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Jan	NEWA

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

>D>	AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005	Feb	CAHN
>A>	AB	NOSTRUM LABS INC	8MG	A076723	001	Oct 18, 2005	Feb	CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

>D>	AP1	AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Feb	DISC
>A>		@	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Feb	DISC
	AP1		1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan	CMS1

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS

IBUPROFEN LYSINE

>D>	AP	X-GEN PHARMS INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Feb	CAHN
>A>	AP	XGEN PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Feb	CAHN

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

ICATIBANT ACETATE

>A>	AP		JIANGSU HANSOH PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211021	001	Mar 09, 2020	Feb NEWA

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

	AB		ANI PHARMS INC	1.25MG	A075201	001	Dec 04, 1998	Jan CAHN
	AB			2.5MG	A075201	002	Dec 04, 1998	Jan CAHN

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

	AB		HERITAGE	25MG	N018851	001	May 18, 1984	Jan CAHN
	AB			50MG	N018851	002	May 18, 1984	Jan CAHN

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

HUMALOG KWIKPEN

		+!	LILLY	200UNITS/ML	N020563	004	Jan 06, 2017	Jan CMS1

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

	AB		APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Jan CMFD

IRBESARTAN

TABLET;ORAL

IRBESARTAN

>D>	AB		HIKMA	75MG	A090201	001	Oct 15, 2012	Feb DISC
>A>		@		75MG	A090201	001	Oct 15, 2012	Feb DISC
>D>	AB			150MG	A090201	002	Oct 15, 2012	Feb DISC
>A>		@		150MG	A090201	002	Oct 15, 2012	Feb DISC
>D>	AB			300MG	A090201	003	Oct 15, 2012	Feb DISC
>A>		@		300MG	A090201	003	Oct 15, 2012	Feb DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

>D>	AB		HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Feb DISC
>A>		@		30MG	A076813	002	Mar 30, 2006	Feb DISC
>D>	AB			60MG	A076813	001	Jan 07, 2005	Feb DISC
>A>		@		60MG	A076813	001	Jan 07, 2005	Feb DISC

ITRACONAZOLE

SOLUTION;ORAL

ITRACONAZOLE

>D>	AA		APOTEX	10MG/ML	A208481	001	Aug 02, 2019	Feb DISC
>A>		@		10MG/ML	A208481	001	Aug 02, 2019	Feb DISC

KETOROLAC TROMETHAMINE

TABLET;ORAL

KETOROLAC TROMETHAMINE

>D>	AB	!	MYLAN	10MG	A074761	001	May 16, 1997	Feb CHRS
>A>	AB			10MG	A074761	001	May 16, 1997	Feb CHRS
>D>	AB		TEVA	10MG	A074754	001	May 16, 1997	Feb CHRS
>A>	AB	!		10MG	A074754	001	May 16, 1997	Feb CHRS

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

NORMODYNE

		+ @	SCHERING	5MG/ML	N018686	001	Aug 01, 1984	Jan CRLD

TABLET;ORAL

LABETALOL HYDROCHLORIDE

>D>		@	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Feb CMFD
>A>	AB			100MG	A074787	001	Aug 03, 1998	Feb CMFD
>D>		@		200MG	A074787	002	Aug 03, 1998	Feb CMFD
>A>	AB			200MG	A074787	002	Aug 03, 1998	Feb CMFD

>A>		LACTITOL						
>A>		FOR SOLUTION;ORAL						
>A>		PIZENSY						
>A>	+!	BRAINTREE LABS	10GM	N211281	001	Feb 12, 2020	Feb	NEWA
>A>	+		10GM/PACKET	N211281	001	Feb 12, 2020	Feb	NEWA
		LASMIDITAN SUCCINATE						
		TABLET;ORAL						
		REYVOW						
	+	ELI LILLY AND CO	50MG	N211280	001	Jan 31, 2020	Jan	NEWA
	+!		100MG	N211280	002	Jan 31, 2020	Jan	NEWA
		LEFLUNOMIDE						
		TABLET;ORAL						
		LEFLUNOMIDE						
	AB	LUPIN LTD	10MG	A211863	001	Feb 04, 2020	Jan	NEWA
	AB		20MG	A211863	002	Feb 04, 2020	Jan	NEWA
		LEVETIRACETAM						
		INJECTABLE;INTRAVENOUS						
		LEVETIRACETAM						
>D>	AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
>A>	AP	XGEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
		LEVOCETIRIZINE DIHYDROCHLORIDE						
		SOLUTION;ORAL						
		LEVOCETIRIZINE DIHYDROCHLORIDE						
>D>	AA	APOTEX	2.5MG/5ML	A202915	001	Aug 21, 2014	Feb	DISC
>A>		@	2.5MG/5ML	A202915	001	Aug 21, 2014	Feb	DISC
		TABLET;ORAL						
		LEVOCETIRIZINE DIHYDROCHLORIDE						
>D>	AB	APOTEX	5MG	A203027	001	Feb 13, 2015	Feb	DISC
>A>		@	5MG	A203027	001	Feb 13, 2015	Feb	DISC
		LEVOTHYROXINE SODIUM **						
		**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium						
		TABLET;ORAL						
		THYRO-TABS						
	AB2, AB4 +	ALVOGEN	0.3MG	N021116	009	Oct 24, 2002	Jan	CHRS
		LINCOMYCIN HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		LINCOMYCIN						
>D>	AP	X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Feb	CAHN
>A>	AP	XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Feb	CAHN
		LIOTHYRONINE SODIUM						
		INJECTABLE;INJECTION						
		LIOTHYRONINE SODIUM						
>D>	AP	X GEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb	CAHN
>A>	AP	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb	CAHN
		TABLET;ORAL						
		LIOTHYRONINE SODIUM						
	AB	SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan	CMFD
	AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan	CMFD
	AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan	CMFD
		LISINOPRIL						
		TABLET;ORAL						
		LISINOPRIL						
>D>	AB	APOTEX INC	2.5MG	A076102	001	Sep 30, 2002	Feb	CAHN
>D>	AB		5MG	A076102	002	Sep 30, 2002	Feb	CAHN
>D>	AB		10MG	A076102	003	Sep 30, 2002	Feb	CAHN
>D>	AB		20MG	A076102	004	Sep 30, 2002	Feb	CAHN
>D>	AB		30MG	A076102	005	Sep 30, 2002	Feb	CAHN
>D>	AB		40MG	A076102	006	Sep 30, 2002	Feb	CAHN
>A>	AB	COREPHARMA	2.5MG	A076102	001	Sep 30, 2002	Feb	CAHN
>A>	AB		5MG	A076102	002	Sep 30, 2002	Feb	CAHN
>A>	AB		10MG	A076102	003	Sep 30, 2002	Feb	CAHN
>A>	AB		20MG	A076102	004	Sep 30, 2002	Feb	CAHN

TABLET;ORAL
LISINOPRIL

>A>	AB			30MG	A076102	005	Sep 30, 2002	Feb CAHN
>A>	AB			40MG	A076102	006	Sep 30, 2002	Feb CAHN

LITHIUM CARBONATE

CAPSULE;ORAL
LITHIUM CARBONATE

	AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987	Jan CAHN
	AB	+		300MG	N017812	001		Jan CAHN
	AB	+!		600MG	N017812	003	Jan 28, 1987	Jan CAHN
		@	MYLAN	150MG	A076243	002	Feb 24, 2003	Jan DISC
		@		300MG	A076243	001	Jun 27, 2002	Jan DISC

LITHIUM CITRATE

SYRUP;ORAL
LITHIUM CITRATE

	AA	+!	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN

LORCASERIN HYDROCHLORIDE

TABLET;ORAL
BELVIQ

>D>		+!	EISAI INC	10MG	N022529	001	Jun 27, 2012	Feb DISC
>A>		+ @		10MG	N022529	001	Jun 27, 2012	Feb DISC

TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR

>D>		+!	EISAI INC	20MG	N208524	001	Jul 15, 2016	Feb DISC
>A>		+ @		20MG	N208524	001	Jul 15, 2016	Feb DISC

LOSARTAN POTASSIUM

TABLET;ORAL
LOSARTAN POTASSIUM

>D>	AB		HIKMA	25MG	A077459	001	Oct 06, 2010	Feb DISC
>A>		@		25MG	A077459	001	Oct 06, 2010	Feb DISC
>D>	AB			50MG	A077459	002	Oct 06, 2010	Feb DISC
>A>		@		50MG	A077459	002	Oct 06, 2010	Feb DISC
>D>	AB			100MG	A077459	003	Oct 06, 2010	Feb DISC
>A>		@		100MG	A077459	003	Oct 06, 2010	Feb DISC

LOVASTATIN

TABLET;ORAL
LOVASTATIN

>D>	AB		APOTEX INC	10MG	A077748	001	Feb 28, 2007	Feb CAHN
>D>	AB			20MG	A077748	002	Feb 28, 2007	Feb CAHN
>D>	AB			40MG	A077748	003	Feb 28, 2007	Feb CAHN
>A>	AB		COREPHARMA	10MG	A077748	001	Feb 28, 2007	Feb CAHN
>A>	AB			20MG	A077748	002	Feb 28, 2007	Feb CAHN
>A>	AB			40MG	A077748	003	Feb 28, 2007	Feb CAHN

MAZINDOL

TABLET;ORAL
SANOREX

		+ @	NOVARTIS	1MG	N017247	001		Jan CAHN
		+ @		2MG	N017247	002		Jan CAHN

MECLIZINE HYDROCHLORIDE

TABLET;ORAL
MECLIZINE HYDROCHLORIDE

		@	MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012	Jan DISC
		@		25MG	A202640	002	Sep 17, 2012	Jan DISC

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL
MEFLOQUINE HYDROCHLORIDE

>D>	AB	!	BARR	250MG	A076392	001	Dec 29, 2003	Feb CTEC
>A>		!		250MG	A076392	001	Dec 29, 2003	Feb CTEC
>D>	AB		HIKMA	250MG	A076523	001	Oct 01, 2004	Feb DISC
>A>		@		250MG	A076523	001	Oct 01, 2004	Feb DISC

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGESTROL ACETATE

>D>	AB	!	HIKMA	40MG/ML	A075997	001	Feb 15, 2002	Feb DISC
>A>		@		40MG/ML	A075997	001	Feb 15, 2002	Feb DISC
>D>	AB		PAR PHARM	40MG/ML	A075671	001	Jul 25, 2001	Feb CHRS
>A>	AB	!		40MG/ML	A075671	001	Jul 25, 2001	Feb CHRS

MELOXICAM

>A> SOLUTION;INTRAVENOUS

>A> ANJESO

>A>		+!	BAUDAX	30MG/ML (30MG/ML)	N210583	001	Feb 20, 2020	Feb NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

>A>	AP		INGENUS PHARMS LLC	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Feb NEWA
>D>	AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	Feb DISC
>A>		@		EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	Feb DISC
		@	TWI PHARMS	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Jan DISC

POWDER;INTRAVENOUS

EVOMELA

>D>		+!	ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Feb CFTG
>A>	AP	+!		EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Feb CFTG

>A> MELPHALAN HYDROCHLORIDE

>A>	AP		ACTAVIS LLC	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020	Feb NFTG

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

>A>	AB		ANI PHARMS INC	7MG	A205365	001	Feb 28, 2020	Feb NEWA
>A>	AB			14MG	A205365	002	Feb 28, 2020	Feb NEWA
>A>	AB			21MG	A205365	003	Feb 28, 2020	Feb NEWA
>A>	AB			28MG	A205365	004	Feb 28, 2020	Feb NEWA

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>A>	AB		HIKMA PHARMS	5MG	A208173	001	Feb 28, 2020	Feb NEWA
>A>	AB			10MG	A208173	002	Feb 28, 2020	Feb NEWA

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

>D>	AA		EPIC PHARMA	50MG	A040331	001	May 28, 1999	Feb CHRS
>A>	AA	!		50MG	A040331	001	May 28, 1999	Feb CHRS
>D>	AA			100MG	A040331	002	May 28, 1999	Feb CHRS
>A>	AA	!		100MG	A040331	002	May 28, 1999	Feb CHRS
>D>	AA	!	HIKMA	50MG	A040110	001	Mar 12, 1997	Feb DISC
>A>		@		50MG	A040110	001	Mar 12, 1997	Feb DISC
>D>	AA	!		100MG	A040110	002	Mar 12, 1997	Feb DISC
>A>		@		100MG	A040110	002	Mar 12, 1997	Feb DISC

MESALAMINE

SUPPOSITORY;RECTAL

MESALAMINE

	AB		ZYDUS PHARMS	1GM	A208953	001	Feb 12, 2020	Jan NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

>A> METFORMIN HYDROCHLORIDE

>A>	AB		SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Feb NFTG

RIOMET

>D>		+!	RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Feb CFTG
>A>	AB	+!		500MG/5ML	N021591	001	Sep 11, 2003	Feb CFTG
		+!		500MG/5ML	N021591	001	Sep 11, 2003	Jan CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

		@	MYLAN	500MG	A075976	001	Jan 24, 2002	Jan DISC
		@		850MG	A075976	002	Jan 24, 2002	Jan DISC
		@		1GM	A075976	003	Jan 24, 2002	Jan DISC

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

>D>	AA	HIKMA INTL PHARMS	500MG	A085159	001			Feb DISC
>A>		@	500MG	A085159	001			Feb DISC
>D>	AA		750MG	A085123	001			Feb DISC
>A>		@	750MG	A085123	001			Feb DISC

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

		@ MYLAN LABS LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012		Jan DISC
		@	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012		Jan DISC
		@	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012		Jan DISC
		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012		Jan CTEC

TABLET;ORAL

METHOTREXATE SODIUM

	AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A213343	001	Jan 24, 2020		Jan NEWA
	AB	EUGIA PHARMA	EQ 2.5MG BASE	A210454	001	Jan 30, 2020		Jan NEWA

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

		@ ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009		Jan DISC
		@	EQ 100MG TARTRATE	A077298	001	Apr 15, 2010		Jan DISC
		@	EQ 200MG TARTRATE	A077298	002	Apr 15, 2010		Jan DISC

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

>D>	AB	HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995		Feb DISC
>A>		@	50MG	A074141	001	Jan 31, 1995		Feb DISC
>D>	AB		100MG	A074141	002	Jan 31, 1995		Feb DISC
>A>		@	100MG	A074141	002	Jan 31, 1995		Feb DISC
	AB	YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020		Jan NEWA
	AB		50MG	A208955	002	Feb 05, 2020		Jan NEWA
	AB		100MG	A208955	003	Feb 05, 2020		Jan NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

		@ MYLAN ASI	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010		Jan DISC
		@	EQ 5MG BASE/ML	A090315	002	Nov 29, 2010		Jan DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

>A>		JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012		Feb CAHN
>A>		@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012		Feb CAHN
>A>			EQ 90MG BASE	N201922	003	Jul 11, 2012		Feb CAHN
>A>		@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012		Feb CAHN
>A>			EQ 135MG BASE	N201922	005	Jul 11, 2012		Feb CAHN
>D>		SUN PHARM INDS INC	EQ 45MG BASE	N201922	001	Jul 11, 2012		Feb CAHN
>D>		@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012		Feb CAHN
>D>			EQ 90MG BASE	N201922	003	Jul 11, 2012		Feb CAHN
>D>		@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012		Feb CAHN
>D>			EQ 135MG BASE	N201922	005	Jul 11, 2012		Feb CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

		@ SAWAI USA	25MG	A209446	001	Dec 27, 2019		Jan DISC

MYRBETRIQ

	+!	APGDI	25MG	N202611	001	Jun 28, 2012		Jan CTEC

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

>A>	AB		AUROBINDO PHARMA LTD	EQ 4MG BASE/PACKET	A213471	001	Feb 18, 2020	Feb NEWA

TABLET;ORAL

MONTELUKAST SODIUM

>D>	AB		HIKMA	EQ 10MG BASE	A090655	001	Aug 03, 2012	Feb DISC
>A>		@		EQ 10MG BASE	A090655	001	Aug 03, 2012	Feb DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

		@	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Jan DISC
		@		EQ 5MG BASE	A203795	002	Feb 27, 2015	Jan DISC

MORPHINE SULFATE

INJECTABLE;INJECTION

DURAMORPH PF

>A>	AP	+!	HIKMA	0.5MG/ML	N018565	001	Sep 18, 1984	Feb CAHN
>A>	AP	+!		1MG/ML	N018565	002	Sep 18, 1984	Feb CAHN
>D>	AP	+!	WEST-WARD PHARMS INT	0.5MG/ML	N018565	001	Sep 18, 1984	Feb CAHN
>D>	AP	+!		1MG/ML	N018565	002	Sep 18, 1984	Feb CAHN

INFUMORPH

>A>	AP	+!	HIKMA	10MG/ML	N018565	003	Jul 19, 1991	Feb CAHN
>A>	AP	+!		25MG/ML	N018565	004	Jul 19, 1991	Feb CAHN
>D>	AP	+!	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991	Feb CAHN
>D>	AP	+!		25MG/ML	N018565	004	Jul 19, 1991	Feb CAHN

MORPHINE SULFATE

>D>	AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	Feb CAHN
>D>	AP			8MG/ML	A205758	002	May 21, 2015	Feb CAHN
>D>	AP			10MG/ML	A205758	003	May 21, 2015	Feb CAHN
>A>	AP		HIKMA	4MG/ML	A205758	001	May 21, 2015	Feb CAHN
>A>	AP			8MG/ML	A205758	002	May 21, 2015	Feb CAHN
>A>	AP			10MG/ML	A205758	003	May 21, 2015	Feb CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

>D>	AP		MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Feb DISC
>A>		@		10MG/ML	A206506	001	Feb 06, 2019	Feb DISC
>D>	AP			10MG/ML	A207595	001	Jan 11, 2019	Feb DISC
>A>		@		10MG/ML	A207595	001	Jan 11, 2019	Feb DISC
>D>	AP			20MG/ML	A206506	002	Feb 06, 2019	Feb DISC
>A>		@		20MG/ML	A206506	002	Feb 06, 2019	Feb DISC
>D>	AP			20MG/ML	A207595	002	Jan 11, 2019	Feb DISC
>A>		@		20MG/ML	A207595	002	Jan 11, 2019	Feb DISC

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

	AP		PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020	Jan NEWA

NAPROXEN

TABLET;ORAL

NAPROXEN

		@	MYLAN	250MG	A074121	001	Dec 21, 1993	Jan DISC
		@		375MG	A074121	002	Dec 21, 1993	Jan DISC
		@		500MG	A074121	003	Dec 21, 1993	Jan DISC
>A>	AB		SCIEGEN PHARMS INC	250MG	A212517	001	Feb 21, 2020	Feb NEWA
>A>	AB			375MG	A212517	002	Feb 21, 2020	Feb NEWA
>A>	AB			500MG	A212517	003	Feb 21, 2020	Feb NEWA

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

>D>	AA		X GEN PHARMS	500MG	A065220	001	Jul 28, 2006	Feb CAHN
>A>	AA		XGEN PHARMS	500MG	A065220	001	Jul 28, 2006	Feb CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

>D>	AT	X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A065106	001	Jan 31, 2006	Feb	CAHN
>D>	AT		EQ 40MG BASE/ML;200,000 UNITS/ML	A065108	001	Jan 31, 2006	Feb	CAHN
>A>	AT	XGEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A065106	001	Jan 31, 2006	Feb	CAHN
>A>	AT		EQ 40MG BASE/ML;200,000 UNITS/ML	A065108	001	Jan 31, 2006	Feb	CAHN

>D> NETARSUDIL DIMESYLATE

>D> SOLUTION/DROPS;OPHTHALMIC

>D> RHOPRESSA

>D>	+!	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Feb	CAIN

>A> NETARSUDIL MESYLATE

>A> SOLUTION/DROPS;OPHTHALMIC

>A> RHOPRESSA

>A>	+!	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Feb	CAIN

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

	@	MYLAN	500MG	A203742	001	Feb 22, 2019	Jan	DISC
	@		750MG	A203742	002	Feb 22, 2019	Jan	DISC
	@		1GM	A203742	003	Feb 22, 2019	Jan	DISC

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

	+!	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Jan	CAHN

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

AB1	+!	TEVA BRANDED PHARM	0.35MG	N017060	001		Jan	CAHN

NYSTATIN

POWDER;TOPICAL

NYSTATIN

>D>	AT	X GEN PHARMS	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Feb	CAHN
>A>	AT	XGEN PHARMS	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Feb	CAHN

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

>D>	AP	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Feb	DISC
>A>		@	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Feb	DISC
>D>	AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Feb	DISC
>A>		@	EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Feb	DISC
>D>	AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Feb	DISC
>A>		@	EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Feb	DISC

SOLUTION;SUBCUTANEOUS

BYNFEZIA PEN

	+!	SUN PHARM	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N213224	001	Jan 28, 2020	Jan	NEWA

OLANZAPINE

TABLET;ORAL

OLANZAPINE

	@	TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Jan	DISC
	@		5MG	A076000	002	Oct 24, 2011	Jan	DISC
	@		7.5MG	A076000	003	Oct 24, 2011	Jan	DISC
	@		10MG	A076000	004	Oct 24, 2011	Jan	DISC
	@		15MG	A076000	005	Oct 24, 2011	Jan	DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

>D>	AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Feb	DISC
>A>		@	5MG	A205482	001	Apr 24, 2017	Feb	DISC
>D>	AB		20MG	A205482	002	Apr 24, 2017	Feb	DISC
>A>		@	20MG	A205482	002	Apr 24, 2017	Feb	DISC

TABLET;ORAL
OLMESARTAN MEDOXOMIL

>D>	AB		40MG		A205482	003	Apr 24, 2017	Feb DISC
>A>		@	40MG		A205482	003	Apr 24, 2017	Feb DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A>	AT		WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Feb NFTG
		PAZEO						
>D>		+!	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Feb CFTG
>A>	AT	+!		EQ 0.7% BASE	N206276	001	Jan 30, 2015	Feb CFTG

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

	AB		AMNEAL PHARMS LLC	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

>D>		@	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Feb CMFD
>A>	AB			1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Feb CMFD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

>D>	AB		MYLAN	10MG	A205070	001	Jun 29, 2018	Feb DISC
>A>		@		10MG	A205070	001	Jun 29, 2018	Feb DISC
		@		20MG	A075876	002	May 29, 2003	Jan DISC
>D>	AB			20MG	A205070	002	Jun 29, 2018	Feb DISC
>A>		@		20MG	A205070	002	Jun 29, 2018	Feb DISC
>D>	AB			40MG	A205070	003	Jun 29, 2018	Feb DISC
>A>		@		40MG	A205070	003	Jun 29, 2018	Feb DISC

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE

		@	MYLAN	EQ 4MG BASE	A076930	001	Jun 25, 2007	Jan DISC
		@		EQ 8MG BASE	A076930	002	Jun 25, 2007	Jan DISC

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

>A>	AB		SUNSHINE LAKE	EQ 30MG BASE	A212739	001	Mar 04, 2020	Feb NEWA
>A>	AB			EQ 45MG BASE	A212739	002	Mar 04, 2020	Feb NEWA
>A>	AB			EQ 75MG BASE	A212739	003	Mar 04, 2020	Feb NEWA

OXCARBAZEPINE

TABLET;ORAL
OXCARBAZEPINE

>D>	AB		HIKMA	150MG	A077795	001	Oct 09, 2007	Feb DISC
>A>		@		150MG	A077795	001	Oct 09, 2007	Feb DISC
>D>	AB			300MG	A077795	002	Oct 09, 2007	Feb DISC
>A>		@		300MG	A077795	002	Oct 09, 2007	Feb DISC
>D>	AB			600MG	A077795	003	Oct 09, 2007	Feb DISC
>A>		@		600MG	A077795	003	Oct 09, 2007	Feb DISC

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL
OXYBUTYNIN CHLORIDE

		@	MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006	Jan DISC
		@		15MG	A076644	002	May 10, 2007	Jan DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

		@	ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan DISC
	AA		AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan NEWA
	AA			100MG/5ML	A212429	002	Jan 27, 2020	Jan NEWA
>D>	AA		HIKMA	100MG/5ML	A203208	001	Jul 12, 2013	Feb DISC

		SOLUTION;ORAL						
		OXYCODONE HYDROCHLORIDE						
>A>		@	100MG/5ML	A203208	001	Jul 12, 2013	Feb DISC	
		PAROXETINE HYDROCHLORIDE						
		TABLET;ORAL						
		PAROXETINE HYDROCHLORIDE						
		@ JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan DISC	
		@	EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan DISC	
		@	EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan DISC	
		@	EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan DISC	
		PASIREOTIDE DIASPARTATE						
		SOLUTION;SUBCUTANEOUS						
		SIGNIFOR						
>D>	+	NOVARTIS	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012	Feb CAHN	
>D>	+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012	Feb CAHN	
>D>	+!		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012	Feb CAHN	
>A>	+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012	Feb CAHN	
>A>	+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012	Feb CAHN	
>A>	+!		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012	Feb CAHN	
		PASIREOTIDE PAMOATE						
		FOR SUSPENSION;INTRAMUSCULAR						
		SIGNIFOR LAR KIT						
>D>	+	NOVARTIS	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Feb CAHN	
>D>	+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Feb CAHN	
>D>	+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Feb CAHN	
>D>	+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Feb CAHN	
>D>	+!		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Feb CAHN	
>A>	+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Feb CAHN	
>A>	+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Feb CAHN	
>A>	+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Feb CAHN	
>A>	+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Feb CAHN	
>A>	+!		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Feb CAHN	
		PAZOPANIB HYDROCHLORIDE						
		TABLET;ORAL						
		VOTRIENT						
	+ @	NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009	Jan CRLD	
		PEGVISOMANT						
		INJECTABLE;SUBCUTANEOUS						
		SOMAVERT						
	+!	PHARMACIA	10MG/VIAL	N021106	001	Mar 25, 2003	Jan CAHN	
	+!		15MG/VIAL	N021106	002	Mar 25, 2003	Jan CAHN	
	+!		20MG/VIAL	N021106	003	Mar 25, 2003	Jan CAHN	
	+!		25MG/VIAL	N021106	004	Jul 31, 2014	Jan CAHN	
	+!		30MG/VIAL	N021106	005	Jul 31, 2014	Jan CAHN	
		PEMETREXED						
>A>		SOLUTION;INTRAVENOUS						
>A>		PEMFEXY						
>A>	+!	EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020	Feb NEWA	
		PENICILLAMINE						
		CAPSULE;ORAL						
		PENICILLAMINE						
AB		ANI PHARMS INC	250MG	A209921	001	May 07, 2019	Jan CAHN	
		TABLET;ORAL						
		PENICILLAMINE						
>A> AB		TEVA PHARMS USA	250MG	A211497	001	Feb 13, 2020	Feb NEWA	

PERMETHRIN

CREAM;TOPICAL

ELIMITE

>D>	AB	+!	MYLAN	5%	N019855	001	Aug 25, 1989	Feb DISC
>A>		+ @		5%	N019855	001	Aug 25, 1989	Feb DISC

PERMETHRIN

>D>	AB		PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	Feb CHRS
>A>	AB	!		5%	A076369	001	Apr 21, 2003	Feb CHRS

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

	AP1		RICONPHARMA LLC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jan NEWA
	AP1			50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jan NEWA
	AP1			100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jan NEWA

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

>D>	AB		AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Feb DISC
>A>		@		5MG	A212377	001	Aug 13, 2019	Feb DISC
>D>	AB			7.5MG	A212377	002	Aug 13, 2019	Feb DISC
>A>		@		7.5MG	A212377	002	Aug 13, 2019	Feb DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

		@	MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012	Jan DISC
		@		EQ 30MG BASE	A076801	002	Aug 17, 2012	Jan DISC
		@		EQ 45MG BASE	A076801	003	Aug 17, 2012	Jan DISC

PODOFILOX

SOLUTION;TOPICAL

CONDYLOX

	AT	+!	TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Jan CAHN

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

AEROSPORIN

		@	GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL	A062036	001		Jan CMS1

POLYMYXIN B SULFATE

>D>	AP		X GEN PHARMS	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb CAHN
>A>	AP		XGEN PHARMS	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb CAHN

POTASSIUM CHLORIDE

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MICRO-K LS

>D>		@	KV PHARM	20MEQ/PACKET	N019561	003	Aug 26, 1988	Feb CRLD
>A>		+ @		20MEQ/PACKET	N019561	003	Aug 26, 1988	Feb CRLD

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>A>	AB2		GRANULES PHARMS	8MEQ	A211797	001	Mar 04, 2020	Feb NEWA
>A>	AB2			10MEQ	A211797	002	Mar 04, 2020	Feb NEWA
>D>		@	PII	8MEQ	A206881	001	Jan 22, 2019	Feb CAHN
>D>		@		10MEQ	A206881	002	Jan 22, 2019	Feb CAHN
>D>		@		10MEQ	A210097	001	Jun 17, 2019	Feb CAHN
>D>		@		20MEQ	A210098	001	Apr 26, 2019	Feb CAHN
>A>		@	STRIDES PHARMA	8MEQ	A206881	001	Jan 22, 2019	Feb CAHN
>A>		@		10MEQ	A206881	002	Jan 22, 2019	Feb CAHN
>A>		@		10MEQ	A210097	001	Jun 17, 2019	Feb CAHN
>A>		@		20MEQ	A210098	001	Apr 26, 2019	Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB		APOTEX INC	0.125MG	A090151	001	Apr 30, 2012	Feb CAHN
>D>	AB			0.25MG	A090151	002	Apr 30, 2012	Feb CAHN
>D>	AB			0.5MG	A090151	003	Apr 30, 2012	Feb CAHN
>D>	AB			0.75MG	A090151	006	Apr 30, 2012	Feb CAHN
>D>	AB			1MG	A090151	004	Apr 30, 2012	Feb CAHN
>D>	AB			1.5MG	A090151	005	Apr 30, 2012	Feb CAHN

TABLET;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

		@	MYLAN	0.125MG	A077854	001	Oct 08, 2010	Jan DISC
		@		0.25MG	A077854	002	Oct 08, 2010	Jan DISC
		@		0.5MG	A077854	003	Oct 08, 2010	Jan DISC
		@		0.75MG	A090764	001	Apr 09, 2010	Jan DISC
		@		1MG	A077854	004	Oct 08, 2010	Jan DISC
		@		1.5MG	A077854	005	Oct 08, 2010	Jan DISC
>A>	AB		ZENNOVA	0.125MG	A090151	001	Apr 30, 2012	Feb CAHN
>A>	AB			0.25MG	A090151	002	Apr 30, 2012	Feb CAHN
>A>	AB			0.5MG	A090151	003	Apr 30, 2012	Feb CAHN
>A>	AB			0.75MG	A090151	006	Apr 30, 2012	Feb CAHN
>A>	AB			1MG	A090151	004	Apr 30, 2012	Feb CAHN
>A>	AB			1.5MG	A090151	005	Apr 30, 2012	Feb CAHN

PREDNICARBATE
OINTMENT;TOPICAL

>D>			DERMATOP					
>D>	AB	+!	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Feb DISC
>A>		+ @		0.1%	N019568	001	Sep 23, 1991	Feb DISC
			PREDNICARBATE					
>D>	AB		FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Feb CHRS
>A>		!		0.1%	A077236	001	Mar 09, 2007	Feb CTEC
>A>	AB	!		0.1%	A077236	001	Mar 09, 2007	Feb CHRS

PREDNISOLONE ACETATE
SUSPENSION/DROPS;OPHTHALMIC
OMNIPRED

	AB	+!	NOVARTIS	1%	N017469	001		Jan CHRS
	AB	+		1%	N017469	001		Jan CRLD

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION;ORAL
PREDNISOLONE SODIUM PHOSPHATE

>A>			PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Feb NEWA

PREGABALIN
CAPSULE;ORAL
PREGABALIN

>D>	AB		MYLAN	25MG	A091228	001	Sep 20, 2019	Feb DISC
>A>		@		25MG	A091228	001	Sep 20, 2019	Feb DISC
>D>	AB			50MG	A091228	002	Sep 20, 2019	Feb DISC
>A>		@		50MG	A091228	002	Sep 20, 2019	Feb DISC
>D>	AB			75MG	A091228	003	Sep 20, 2019	Feb DISC
>A>		@		75MG	A091228	003	Sep 20, 2019	Feb DISC
>D>	AB			100MG	A091228	004	Sep 20, 2019	Feb DISC
>A>		@		100MG	A091228	004	Sep 20, 2019	Feb DISC
>D>	AB			150MG	A091228	005	Sep 20, 2019	Feb DISC
>A>		@		150MG	A091228	005	Sep 20, 2019	Feb DISC
>D>	AB			200MG	A091228	006	Sep 20, 2019	Feb DISC
>A>		@		200MG	A091228	006	Sep 20, 2019	Feb DISC
>D>	AB			225MG	A091228	007	Sep 20, 2019	Feb DISC
>A>		@		225MG	A091228	007	Sep 20, 2019	Feb DISC
>D>	AB			300MG	A091228	008	Sep 20, 2019	Feb DISC
>A>		@		300MG	A091228	008	Sep 20, 2019	Feb DISC

PROMETHAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE

>D>	AP		X-GEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008	Feb CAHN
>D>	AP			50MG/ML	A040737	002	Apr 24, 2008	Feb CAHN
>A>	AP		XGEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008	Feb CAHN
>A>	AP			50MG/ML	A040737	002	Apr 24, 2008	Feb CAHN

PYRAZINAMIDE
TABLET;ORAL
PYRAZINAMIDE

>D>	AB		AKORN	500MG	A081319	001	Jun 30, 1992	Feb CTEC
>A>		!		500MG	A081319	001	Jun 30, 1992	Feb CHRS
>A>				500MG	A081319	001	Jun 30, 1992	Feb CTEC
>D>	AB	!	DAVA PHARMS INC	500MG	A080157	001		Feb DISC
>A>		@		500MG	A080157	001		Feb DISC

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

>D>		+!	VYERA PHARMS LLC	25MG	N008578	001		Feb CFTG
>A>	AB	+!		25MG	N008578	001		Feb CFTG

PYRIMETHAMINE

>A>	AB		CEROVENE INC	25MG	A207127	001	Feb 28, 2020	Feb NFTG

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

>D>	AB		APOTEX INC	EQ 25MG BASE	A090960	001	Mar 27, 2012	Feb CAHN
>D>	AB			EQ 50MG BASE	A090960	002	Mar 27, 2012	Feb CAHN
>D>	AB			EQ 100MG BASE	A090960	003	Mar 27, 2012	Feb CAHN
>D>	AB			EQ 200MG BASE	A090960	004	Mar 27, 2012	Feb CAHN
>D>	AB			EQ 300MG BASE	A090960	005	Mar 27, 2012	Feb CAHN
>D>	AB			EQ 400MG BASE	A090960	006	Mar 27, 2012	Feb CAHN
>A>	AB		ZENNOVA	EQ 25MG BASE	A090960	001	Mar 27, 2012	Feb CAHN
>A>	AB			EQ 50MG BASE	A090960	002	Mar 27, 2012	Feb CAHN
>A>	AB			EQ 100MG BASE	A090960	003	Mar 27, 2012	Feb CAHN
>A>	AB			EQ 200MG BASE	A090960	004	Mar 27, 2012	Feb CAHN
>A>	AB			EQ 300MG BASE	A090960	005	Mar 27, 2012	Feb CAHN
>A>	AB			EQ 400MG BASE	A090960	006	Mar 27, 2012	Feb CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

		@	AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006	Jan DISC
		@		EQ 300MG BASE	A077824	002	Oct 13, 2006	Jan DISC
		@	STRIDES PHARMA	EQ 150MG BASE	A210010	001	Aug 01, 2018	Jan DISC
	AB	!		EQ 300MG BASE	A205512	002	Aug 22, 2016	Jan CHRS
		@		EQ 300MG BASE	A210010	002	Aug 01, 2018	Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

	AB		ANI PHARMS INC	500MG	A210482	001	Oct 29, 2019	Jan CAHN
	AB			1GM	A210482	002	Oct 29, 2019	Jan CAHN
	AB		MANKIND PHARMA	500MG	A212284	001	Feb 12, 2020	Jan NEWA
	AB			1GM	A212284	002	Feb 12, 2020	Jan NEWA
>A>	AB		MICRO LABS	500MG	A211745	001	Feb 27, 2020	Feb NEWA
>A>	AB			1GM	A211745	002	Feb 27, 2020	Feb NEWA

RIBAVIRIN

CAPSULE;ORAL

RIBASPHERE

>D>	AB		KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Feb DISC
>A>		@		200MG	A076203	001	Apr 06, 2004	Feb DISC

TABLET;ORAL

RIBAVIRIN

>D>	AB		BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb DISC
>A>		@		200MG	A202546	001	Aug 12, 2014	Feb DISC
>D>	AB			400MG	A202546	002	Aug 12, 2014	Feb DISC
>A>		@		400MG	A202546	002	Aug 12, 2014	Feb DISC
>D>	AB			500MG	A202546	003	Aug 12, 2014	Feb DISC
>A>		@		500MG	A202546	003	Aug 12, 2014	Feb DISC
>D>	AB			600MG	A202546	004	Aug 12, 2014	Feb DISC
>A>		@		600MG	A202546	004	Aug 12, 2014	Feb DISC
>D>	AB		KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Feb DISC
>A>		@		200MG	A077456	001	Dec 05, 2005	Feb DISC
>D>	AB			400MG	A077456	002	Dec 05, 2005	Feb DISC
>A>		@		400MG	A077456	002	Dec 05, 2005	Feb DISC
>D>	AB	!		600MG	A077456	003	Dec 05, 2005	Feb DISC
>A>		@		600MG	A077456	003	Dec 05, 2005	Feb DISC
>D>	AB		ZYDUS PHARMS USA	400MG	A077094	002	Mar 16, 2007	Feb DISC
>A>		@		400MG	A077094	002	Mar 16, 2007	Feb DISC
>D>	AB			500MG	A077094	004	Apr 18, 2008	Feb DISC
>A>		@		500MG	A077094	004	Apr 18, 2008	Feb DISC
>D>	AB			600MG	A077094	003	Mar 16, 2007	Feb DISC
>A>		@		600MG	A077094	003	Mar 16, 2007	Feb DISC

>A> RIMEGEPANT SULFATE
>A> TABLET, ORALLY DISINTEGRATING;ORAL
>A> NURTEC ODT

>A>	+!	BIOHAVEN PHARM	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb NEWA

RITODRINE HYDROCHLORIDE
INJECTABLE;INJECTION
YUTOPAR

	@	ASTRAZENECA	15MG/ML	N018580	002	Sep 27, 1984	Jan CMS1

RIZATRIPTAN BENZOATE
TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

>D> AB		MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012	Feb DISC
>A>	@		EQ 5MG BASE	A078173	001	Dec 31, 2012	Feb DISC
>D> AB			EQ 10MG BASE	A078173	002	Dec 31, 2012	Feb DISC
>A>	@		EQ 10MG BASE	A078173	002	Dec 31, 2012	Feb DISC

ROPINIROLE HYDROCHLORIDE
TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

>D> AB		HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008	Feb DISC
>A>	@		EQ 0.25MG BASE	A077852	001	May 05, 2008	Feb DISC
>D> AB			EQ 0.5MG BASE	A077852	002	May 05, 2008	Feb DISC
>A>	@		EQ 0.5MG BASE	A077852	002	May 05, 2008	Feb DISC
>D> AB			EQ 1MG BASE	A077852	003	May 05, 2008	Feb DISC
>A>	@		EQ 1MG BASE	A077852	003	May 05, 2008	Feb DISC
>D> AB			EQ 2MG BASE	A077852	004	May 05, 2008	Feb DISC
>A>	@		EQ 2MG BASE	A077852	004	May 05, 2008	Feb DISC
>D> AB			EQ 3MG BASE	A077852	005	May 05, 2008	Feb DISC
>A>	@		EQ 3MG BASE	A077852	005	May 05, 2008	Feb DISC
>D> AB			EQ 4MG BASE	A077852	006	May 05, 2008	Feb DISC
>A>	@		EQ 4MG BASE	A077852	006	May 05, 2008	Feb DISC
>D> AB			EQ 5MG BASE	A077852	007	May 19, 2008	Feb DISC
>A>	@		EQ 5MG BASE	A077852	007	May 19, 2008	Feb DISC

SELEGILINE HYDROCHLORIDE
CAPSULE;ORAL
SELEGILINE HYDROCHLORIDE

>D> AB		DAVA PHARMS INC	5MG	A075352	001	Nov 30, 1998	Feb DISC
>A>	@		5MG	A075352	001	Nov 30, 1998	Feb DISC

SELEXIPAG
TABLET;ORAL
UPTRAVI

	+!	ACTELION PHARMS LTD	0.4MG	N207947	002	Dec 21, 2015	Jan CHRS
	+		1.6MG	N207947	008	Dec 21, 2015	Jan CHRS

SEMAGLUTIDE
SOLUTION;SUBCUTANEOUS
OZEMPIC

	+!	NOVO	4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019	Jan NEWA

SILDENAFIL CITRATE
TABLET;ORAL
SILDENAFIL CITRATE

>A> AB		APPCO	25MG	A207178	001	Mar 02, 2020	Feb NEWA
>A> AB			50MG	A207178	002	Mar 02, 2020	Feb NEWA
>A> AB			100MG	A207178	003	Mar 02, 2020	Feb NEWA

SILODOSIN
CAPSULE;ORAL
SILODOSIN

>A> AB		HETERO LABS LTD V	4MG	A204793	001	Feb 14, 2020	Feb NEWA
>A> AB			8MG	A204793	002	Feb 14, 2020	Feb NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

>A>	AA		CURIUM	100uCi	A071909	001	Feb 28, 1989	Feb CAHN
>A>	AA			200uCi	A071910	001	Feb 28, 1989	Feb CAHN
>D>	AA		MALLINKRODT NUCLEAR	100uCi	A071909	001	Feb 28, 1989	Feb CAHN
>D>	AA			200uCi	A071910	001	Feb 28, 1989	Feb CAHN

SODIUM IODIDE I-131

SOLUTION;ORAL

HICON

	AA	+!	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011	Jan CFTG

SODIUM IODIDE I 131

	AA		INTL ISOTOPES	250-1000mCi	A209166	001	Feb 05, 2020	Jan NFTG

SODIUM PHENYLBUTYRATE

TABLET;ORAL

SODIUM PHENYLBUTYRATE

		@	ALVOGEN	500MG	A090910	001	Nov 18, 2011	Jan DISC

SODIUM POLYSTYRENE SULFONATE

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>D>	AA		HIKMA	15GM/60ML	A089049	001	Nov 17, 1986	Feb DISC
>A>		@		15GM/60ML	A089049	001	Nov 17, 1986	Feb DISC

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SUNOSI

		+	JAZZ	EQ 75MG BASE	N211230	001	Jun 17, 2019	Jan CPOT
		+		75MG	N211230	001	Jun 17, 2019	Jan CAIN
		+		EQ 150MG BASE	N211230	002	Jun 17, 2019	Jan CPOT
		+		150MG	N211230	002	Jun 17, 2019	Jan CAIN

SOMATROPIN

INJECTABLE;INJECTION

ACCRETROPIN

		@	EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Jan CAIN

HUMATROPE

		@	LILLY	2MG/VIAL	N019640	001	Jun 23, 1987	Jan CAIN
	BX	+!		5MG/VIAL	N019640	004	Mar 08, 1987	Jan CAIN
	BX	+		6MG/VIAL	N019640	005	Feb 04, 1999	Jan CAIN
		+!		12MG/VIAL	N019640	006	Feb 04, 1999	Jan CAIN
		+!		24MG/VIAL	N019640	007	Feb 04, 1999	Jan CAIN

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

>D>		!	X GEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998	Feb CAHN
>A>		!	XGEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998	Feb CAHN

SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN SUCCINATE

>D>	AB		APOTEX INC	EQ 25MG BASE	A200263	001	Jun 19, 2012	Feb CAHN
>D>	AB			EQ 50MG BASE	A200263	002	Jun 19, 2012	Feb CAHN
>D>	AB			EQ 100MG BASE	A200263	003	Jun 19, 2012	Feb CAHN
>A>	AB		COREPHARMA	EQ 25MG BASE	A200263	001	Jun 19, 2012	Feb CAHN
>A>	AB			EQ 50MG BASE	A200263	002	Jun 19, 2012	Feb CAHN
>A>	AB			EQ 100MG BASE	A200263	003	Jun 19, 2012	Feb CAHN

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

>D>		+ @	ASSERTIO	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	Feb CAHN
>A>		+ @	COLLEGIUM PHARM INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	Feb CAHN

TABLET;ORAL

NUCYNTA

>A>		+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Feb CAHN
>A>		+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Feb CAHN
>A>		+!		EQ 100MG BASE	N022304	003	Nov 20, 2008	Feb CAHN

TABLET;ORAL
NUCYNTA

>D>		+	DEPO NF	EQ 50MG BASE	N022304	001	Nov 20, 2008	Feb CAHN
>D>		+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Feb CAHN
>D>		+!		EQ 100MG BASE	N022304	003	Nov 20, 2008	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
NUCYNTA ER

>A>		+	COLLEGIUM PHARM INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	Feb CAHN
>A>		+		EQ 100MG BASE	N200533	002	Aug 25, 2011	Feb CAHN
>A>		+		EQ 150MG BASE	N200533	003	Aug 25, 2011	Feb CAHN
>A>		+		EQ 200MG BASE	N200533	004	Aug 25, 2011	Feb CAHN
>A>		+!		EQ 250MG BASE	N200533	005	Aug 25, 2011	Feb CAHN
>D>		+	DEPO NF	EQ 50MG BASE	N200533	001	Aug 25, 2011	Feb CAHN
>D>		+		EQ 100MG BASE	N200533	002	Aug 25, 2011	Feb CAHN
>D>		+		EQ 150MG BASE	N200533	003	Aug 25, 2011	Feb CAHN
>D>		+		EQ 200MG BASE	N200533	004	Aug 25, 2011	Feb CAHN
>D>		+!		EQ 250MG BASE	N200533	005	Aug 25, 2011	Feb CAHN

TAZEMETOSTAT HYDROBROMIDE

TABLET;ORAL
TAZVERIK

		+!	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020	Jan NEWA

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION
TECHNETIUM TC99M MERTIATIDE KIT

	AP		SOMMER PHARMS II LLC	N/A	A206489	001	Feb 06, 2020	Jan NEWA

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION
TECHNETIUM TC 99M SESTAMIBI

>A>	AP		CURIUM	N/A	A078098	001	Sep 22, 2008	Feb CAHN
>D>	AP		MALLINKRODT NUCLEAR	N/A	A078098	001	Sep 22, 2008	Feb CAHN

TELMISARTAN

TABLET;ORAL
TELMISARTAN

		@	JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Jan DISC
		@		40MG	A204164	002	Aug 22, 2016	Jan DISC
		@		80MG	A204164	003	Aug 22, 2016	Jan DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

>D>	AB		MYLAN	150MG	A206569	001	Nov 27, 2018	Feb DISC
>A>		@		150MG	A206569	001	Nov 27, 2018	Feb DISC
>D>	AB			200MG	A206569	002	Nov 27, 2018	Feb DISC
>A>		@		200MG	A206569	002	Nov 27, 2018	Feb DISC
>D>	AB			250MG	A206569	003	Nov 27, 2018	Feb DISC
>A>		@		250MG	A206569	003	Nov 27, 2018	Feb DISC
>D>	AB			300MG	A206569	004	Nov 27, 2018	Feb DISC
>A>		@		300MG	A206569	004	Nov 27, 2018	Feb DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE

>D>	AB		HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Feb DISC
>A>		@		EQ 1MG BASE	A075614	002	Jan 30, 2001	Feb DISC
>D>	AB			EQ 2MG BASE	A075614	001	Jan 30, 2001	Feb DISC
>A>		@		EQ 2MG BASE	A075614	001	Jan 30, 2001	Feb DISC
>D>	AB			EQ 5MG BASE	A075614	003	Jan 30, 2001	Feb DISC
>A>		@		EQ 5MG BASE	A075614	003	Jan 30, 2001	Feb DISC
>D>	AB			EQ 10MG BASE	A075614	004	Jan 30, 2001	Feb DISC
>A>		@		EQ 10MG BASE	A075614	004	Jan 30, 2001	Feb DISC

TERIFLUNOMIDE

TABLET;ORAL
TERIFLUNOMIDE

>A>	AB		MYLAN	7MG	A209702	001	Feb 28, 2020	Feb NEWA
>A>	AB			14MG	A209702	002	Feb 28, 2020	Feb NEWA

TERIPARATIDE
INJECTABLE;SUBCUTANEOUS
FORTEO
+! LILLY 0.6MG/2.4ML (0.25MG/ML) N021318 002 Jun 25, 2008 Jan CAIN
@ 0.75MG/3ML (0.25MG/ML) N021318 001 Nov 26, 2002 Jan CAIN
SOLUTION;SUBCUTANEOUS
BONSITY
ALVOGEN 0.62MG/2.48ML (0.25MG/ML) N211939 001 Oct 04, 2019 Jan CAIN
FORTEO
+! LILLY 0.6MG/2.4ML (0.25MG/ML) N021318 002 Jun 25, 2008 Jan CDFR
@ 0.75MG/3ML (0.25MG/ML) N021318 001 Nov 26, 2002 Jan CDFR

TETRABENAZINE
TABLET;ORAL
TETRABENAZINE
AB PIRAMAL HLTHCARE UK 12.5MG A213316 001 Jan 22, 2020 Jan NEWA
AB 25MG A213316 002 Jan 22, 2020 Jan NEWA

TETRACYCLINE HYDROCHLORIDE
CAPSULE;ORAL
TETRACYCLINE HYDROCHLORIDE
>A> AB STRIDES PHARMA 250MG A212635 001 Mar 03, 2020 Feb NEWA
>A> AB 500MG A212635 002 Mar 03, 2020 Feb NEWA

THALLOUS CHLORIDE TL-201
INJECTABLE;INTRAVENOUS
THALLOUS CHLORIDE TL 201
>A> @ CURIUM 2mCi/ML A077698 001 Nov 09, 2006 Feb CAHN
>D> @ MALLINKRODT NUCLEAR 2mCi/ML A077698 001 Nov 09, 2006 Feb CAHN

THIOTEPA
POWDER;INTRAVENOUS
TEPADINA
>D> +! ADIENNE SA 15MG/VIAL N208264 001 Jan 26, 2017 Feb CFTG
>A> AP +! 15MG/VIAL N208264 001 Jan 26, 2017 Feb CFTG
>D> +! 100MG/VIAL N208264 002 Jan 26, 2017 Feb CFTG
>A> AP +! 100MG/VIAL N208264 002 Jan 26, 2017 Feb CFTG
>A> THIOTEPA
>A> AP MSN 15MG/VIAL A213049 001 Mar 04, 2020 Feb NFTG
>A> AP 100MG/VIAL A213049 002 Mar 04, 2020 Feb NFTG

TOBRAMYCIN
SOLUTION;INHALATION
TOBRAMYCIN
>D> AN MYLAN 300MG/5ML A209554 001 Oct 13, 2017 Feb DISC
>A> @ 300MG/5ML A209554 001 Oct 13, 2017 Feb DISC

TOBRAMYCIN SULFATE
INJECTABLE;INJECTION
TOBRAMYCIN SULFATE
>D> AP ! X GEN PHARMS EQ 1.2GM BASE/VIAL A065013 001 Aug 17, 2001 Feb CAHN
>A> AP ! XGEN PHARMS EQ 1.2GM BASE/VIAL A065013 001 Aug 17, 2001 Feb CAHN

TOLTERODINE TARTRATE
TABLET;ORAL
TOLTERODINE TARTRATE
@ MYLAN PHARMS INC 1MG A202641 001 Nov 27, 2012 Jan DISC
@ 2MG A202641 002 Nov 27, 2012 Jan DISC
AB UNIQUE PHARM LABS 1MG A204721 001 Jan 24, 2020 Jan NEWA
AB 2MG A204721 002 Jan 24, 2020 Jan NEWA

TORSEMIDE
TABLET;ORAL
TORSEMIDE
>D> AB APOTEX INC 5MG A076894 001 May 31, 2005 Feb CAHN
>D> AB 10MG A076894 002 May 31, 2005 Feb CAHN
>D> AB 20MG A076894 003 May 31, 2005 Feb CAHN
>D> AB 100MG A076894 004 May 31, 2005 Feb CAHN
>A> AB COREPHARMA 5MG A076894 001 May 31, 2005 Feb CAHN
>A> AB 10MG A076894 002 May 31, 2005 Feb CAHN
>A> AB 20MG A076894 003 May 31, 2005 Feb CAHN

		TABLET;ORAL						
		TORSEMIDE						
>A>	AB		100MG	A076894	004	May 31, 2005	Feb	CAHN
		TRANEXAMIC ACID						
		INJECTABLE;INJECTION						
		TRANEXAMIC ACID						
		@ CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jan	DISC
>D>	AP	X-GEN PHARMS INC	100MG/ML	A201580	001	Jun 14, 2013	Feb	CAHN
>A>	AP	XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013	Feb	CAHN
		TABLET;ORAL						
		TRANEXAMIC ACID						
		@ ANI PHARMS INC	650MG	A203256	001	Jul 25, 2016	Jan	CAHN
		TRAZODONE HYDROCHLORIDE						
		TABLET;ORAL						
		TRAZODONE HYDROCHLORIDE						
	AB	AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Jan	NEWA
	AB		100MG	A204852	002	Feb 05, 2020	Jan	NEWA
	AB		150MG	A204852	003	Feb 05, 2020	Jan	NEWA
	AB		300MG	A204852	004	Feb 05, 2020	Jan	NEWA
		TRIAZOLAM						
		TABLET;ORAL						
		TRIAZOLAM						
		@ MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994	Jan	DISC
		@	0.25MG	A074031	002	Mar 25, 1994	Jan	DISC
		TRIENTINE HYDROCHLORIDE						
		CAPSULE;ORAL						
		TRIENTINE HYDROCHLORIDE						
>A>	AB	RISING	250MG	A212238	001	Feb 20, 2020	Feb	NEWA
		URSODIOL						
		CAPSULE;ORAL						
		URSODIOL						
	AB	RISING	300MG	A213200	001	Feb 12, 2020	Jan	NEWA
		VALACYCLOVIR HYDROCHLORIDE						
		TABLET;ORAL						
		VALACYCLOVIR HYDROCHLORIDE						
		@ TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010	Jan	DISC
		@	EQ 1GM BASE	A077655	002	May 24, 2010	Jan	DISC
		VALGANCICLOVIR HYDROCHLORIDE						
		FOR SOLUTION;ORAL						
		VALGANCICLOVIR HYDROCHLORIDE						
	AB	GRANULES PHARMS	50MG/ML	A213306	001	Jan 31, 2020	Jan	NEWA
		VANCOMYCIN HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		VANCOMYCIN HYDROCHLORIDE						
	AP	PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CAHN
	AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CAHN
		VARDENAFIL HYDROCHLORIDE						
		TABLET, ORALLY DISINTEGRATING;ORAL						
		VARDENAFIL HYDROCHLORIDE						
>A>	AB	MACLEODS PHARMS LTD	10MG	A205988	001	Mar 10, 2020	Feb	NEWA
		VINCRISTINE SULFATE						
		INJECTABLE;INJECTION						
		VINCRISTINE SULFATE PFS						
>D>		! HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Feb	CTEC
>A>	AP	!	1MG/ML	A071484	001	Apr 19, 1988	Feb	CTEC
>D>		@ TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Feb	CMFD
>A>	AP		1MG/ML	A075493	001	Sep 01, 1999	Feb	CMFD

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

>A>	AP	INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Feb	NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

>D>	AB	MYLAN	2.5MG	A202855	001	Sep 20, 2019	Feb	DISC
>A>		@	2.5MG	A202855	001	Sep 20, 2019	Feb	DISC
>D>	AB		5MG	A202855	002	Sep 20, 2019	Feb	DISC
>A>		@	5MG	A202855	002	Sep 20, 2019	Feb	DISC

>A>	ACETAMINOPHEN; IBUPROFEN						
>A>	TABLET;ORAL						
>A>	ADVIL DUAL ACTION WITH ACETAMINOPHEN						
>A>	+! PFIZER INC	250MG;125MG	N211733	001	Feb 28, 2020	Feb	NEWA
	FAMOTIDINE						
	TABLET;ORAL						
	FAMOTIDINE						
	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001	Jan	CMS1
	@ MYLAN	10MG	A075674	001	Dec 21, 2001	Jan	DISC
	FEXOFENADINE HYDROCHLORIDE						
	TABLET;ORAL						
	FEXOFENADINE HYDROCHLORIDE						
>A>	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020	Feb	NEWA
>A>		180MG	A212971	002	Feb 24, 2020	Feb	NEWA
	LEVOCETIRIZINE DIHYDROCHLORIDE						
	TABLET;ORAL						
	LEVOCETIRIZINE DIHYDROCHLORIDE						
>D>	@ PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019	Feb	CMFD
>A>		5MG	A211983	001	Mar 28, 2019	Feb	CMFD
	LEVONORGESTREL						
	TABLET;ORAL						
	LEVONORGESTREL						
>D>	APOTEX	1.5MG	A205329	001	Sep 18, 2018	Feb	CAHN
		1.5MG	A205329	001	Sep 18, 2018	Jan	CMFD
	LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018	Jan	CAHN
>A>	XIROMED	1.5MG	A205329	001	Sep 18, 2018	Feb	CAHN
	LORATADINE						
	TABLET;ORAL						
	LORATADINE						
	@ MYLAN	10MG	A075790	001	Nov 07, 2008	Jan	DISC
	@	10MG	A078447	001	Aug 12, 2011	Jan	DISC
	NICOTINE POLACRILEX						
	TROCHE/LOZENGE;ORAL						
	NICOTINE POLACRILEX						
>A>	DR REDDYS LABS SA	EQ 2MG BASE	A212983	001	Feb 21, 2020	Feb	NEWA
>A>		EQ 4MG BASE	A212983	002	Feb 21, 2020	Feb	NEWA
	POLYETHYLENE GLYCOL 3350						
	FOR SOLUTION;ORAL						
	GLYCOLAX						
	LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009	Jan	CMFD
		17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jan	CMFD

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 02 FEBRUARY 2020

NO FEBRUARY 2020 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO FEBRUARY 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN						
A 213115 001					CGT	Jul 28, 2020
AMISULPRIDE - BARHEMSYS						
N 209510 001					>A> NCE	Feb 26, 2025
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 001	>A> 10548943	Dec 16, 2029	U-2739			
	>A> 10548943	Dec 16, 2029	U-2740			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 002	>A> 10548943	Dec 16, 2029	U-2739			
	>A> 10548943	Dec 16, 2029	U-2740			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 002	10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	10517507	Jun 13, 2032	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	10517507	Jun 13, 2032	DP			
AVAPRITINIB - AYVAKIT						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
AVAPRITINIB - AYVAKIT						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVAPRITINIB - AYVAKIT							
N 212608	002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
		9944651	Oct 15, 2034	DS DP U-2726			
		9994575	Oct 15, 2034	DS DP U-2726			
AVAPRITINIB - AYVAKIT							
N 212608	003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
		9944651	Oct 15, 2034	DS DP U-2726			
		9994575	Oct 15, 2034	DS DP U-2726			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	7112592	Jan 07, 2026	DS DP U-2244			
		7112592	Jan 07, 2026	DS DP U-2508			
		7112592	Jan 07, 2026	DS DP U-282			
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE							
A 207712	001					>A> PC	Aug 29, 2020
BEMPEDOIC ACID - NEXLETOL							
N 211616	001	>A> 10118881	Dec 23, 2023	U-2747		>A> NCE	Feb 21, 2025
		>A> 7335799	Dec 03, 2025	DS			
		>A> 8497301	Dec 23, 2023	U-2747			
		>A> 9000041	Dec 23, 2023	U-2747			
		>A> 9624152	Dec 23, 2023	U-2748			
BEMPEDOIC ACID; EZETIMIBE - NEXLIZET							
N 211617	001	>A> 10118881	Dec 23, 2023	U-2746		>A> NCE	Feb 21, 2025
		>A> 7335799	Dec 03, 2025	DS		>A> NP	Feb 26, 2023
		>A> 8497301	Dec 23, 2023	U-2746			
		>A> 9000041	Dec 23, 2023	U-2746			
		>A> 9624152	Dec 23, 2023	U-2749			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY							
N 210251	001	>A> 10548846	Nov 08, 2036	DP			
BRILLIANT BLUE G - TISSUEBLUE							
N 209569	001					NCE	Dec 20, 2024
						ODE-282	Dec 20, 2026
BUPRENORPHINE - SUBLOCADE							
N 209819	001	>A> 10558394	Jun 25, 2031	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	001	>A> 8513202	Dec 03, 2027	DS DP U-2441			
		>A> 8513202	Dec 03, 2027	DS DP U-2632			
		>A> 8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	002	>A> 8513202	Dec 03, 2027	DS DP U-2441			
		>A> 8513202	Dec 03, 2027	DS DP U-2632			
		>A> 8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	003	>A> 8513202	Dec 03, 2027	DS DP U-2441			
		>A> 8513202	Dec 03, 2027	DS DP U-2632			
		>A> 8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	004	>A> 8513202	Dec 03, 2027	DS DP U-2441			
		>A> 8513202	Dec 03, 2027	DS DP U-2632			
		>A> 8513202	Dec 03, 2027	DS DP U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	001	>A> 7943582	Feb 26, 2029	DS DP U-2441			
		>A> 7943582	Feb 26, 2029	DS DP U-2632			
		>A> 7943582	Feb 26, 2029	DS DP U-493			
		>A> 8222219	Apr 11, 2025	U-2441			
		>A> 8222219	Apr 11, 2025	U-2632			
		>A> 8222219	Apr 11, 2025	U-493			
		>A> 8513202	Dec 03, 2027	DS DP U-2441			
		>A> 8513202	Dec 03, 2027	DS DP U-2632			
		>A> 8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	002	>A> 7943582	Feb 26, 2029	DS DP U-2441			
		>A> 7943582	Feb 26, 2029	DS DP U-2632			
		>A> 7943582	Feb 26, 2029	DS DP U-493			
		>A> 8222219	Apr 11, 2025	U-2441			
		>A> 8222219	Apr 11, 2025	U-2632			
		>A> 8222219	Apr 11, 2025	U-493			
		>A> 8513202	Dec 03, 2027	DS DP U-2441			
		>A> 8513202	Dec 03, 2027	DS DP U-2632			
		>A> 8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	003	>A> 7943582	Feb 26, 2029	DS DP U-2441			
		>A> 7943582	Feb 26, 2029	DS DP U-2632			
		>A> 7943582	Feb 26, 2029	DS DP U-493			
		>A> 8222219	Apr 11, 2025	U-2441			
		>A> 8222219	Apr 11, 2025	U-2632			
		>A> 8222219	Apr 11, 2025	U-493			
		>A> 8513202	Dec 03, 2027	DS DP U-2441			
		>A> 8513202	Dec 03, 2027	DS DP U-2632			
		>A> 8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR							
N 205879	004	>A> 7943582	Feb 26, 2029	DS DP U-2441			
		>A> 7943582	Feb 26, 2029	DS DP U-2632			
		>A> 7943582	Feb 26, 2029	DS DP U-493			
		>A> 8222219	Apr 11, 2025	U-2441			
		>A> 8222219	Apr 11, 2025	U-2632			
		>A> 8222219	Apr 11, 2025	U-493			
		>A> 8513202	Dec 03, 2027	DS DP U-2441			
		>A> 8513202	Dec 03, 2027	DS DP U-2632			
		>A> 8513202	Dec 03, 2027	DS DP U-493			
CRISABOROLE - EUCRISA							
N 207695	001	>A> 8039451	Jun 11, 2026	DS DP		>A> NCE	Dec 14, 2021
		>A> 8039451*PED	Dec 11, 2026			>A> PED	Jun 14, 2022
		>A> 8168614	Jan 20, 2030	U-1932			
		>A> 8168614*PED	Jul 20, 2030				
		>A> 8501712	Feb 16, 2027	U-1932			
		>A> 8501712*PED	Aug 16, 2027				
		>A> 9682092	Feb 16, 2027	U-1932			
		>A> 9682092*PED	Aug 16, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	001	>A> 10548859	Aug 16, 2036	U-1399			
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	002	>A> 10548859	Aug 16, 2036	U-1399			
CYSTEINE HYDROCHLORIDE - ELCYS							
N 210660	001	>A> 10478453	Jan 15, 2039	DP U-2752			
		>A> 10583155	Jan 15, 2039	DP U-2752			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEINE HYDROCHLORIDE - NOURESS								
N 212535	001		10493051	Mar 15, 2039	DP			
			10543186	Mar 15, 2039	U-2722			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA								
N 206843	001		8329159	Jul 24, 2029	DS			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA								
N 206843	002		8329159	Jul 24, 2029	DS			
DEFERIPRONE - FERRIPROX								
N 021825	002		7049328	Jun 28, 2021	U-735			
DEOXYCHOLIC ACID - KYBELLA								
N 206333	001		10500214	Mar 02, 2030	DP			
DEXAMETHASONE - HEMADY								
N 211379	001		10537585	Dec 18, 2037	DP			
DIAZEPAM - VALTOCO								
N 211635	001		10265402	May 11, 2025	DP		NP	Jan 10, 2023
			8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
			8927497	Jul 21, 2025	DP U-2727			
			9642913	May 11, 2025	DP			
			9763876	Mar 27, 2029	DP U-2727			
DIAZEPAM - VALTOCO								
N 211635	002		10265402	May 11, 2025	DP		NP	Jan 10, 2023
			8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
			8927497	Jul 21, 2025	DP U-2727			
			9642913	May 11, 2025	DP			
			9763876	Mar 27, 2029	DP U-2727			
DIAZEPAM - VALTOCO								
N 211635	003		10265402	May 11, 2025	DP		NP	Jan 10, 2023
			8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
			8927497	Jul 21, 2025	DP U-2727			
			9642913	May 11, 2025	DP			
			9763876	Mar 27, 2029	DP U-2727			
DOXEPIN HYDROCHLORIDE - SILENOR								
N 022036	001	>A>	10548871	Apr 11, 2028	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR								
N 022036	002	>A>	10548871	Apr 11, 2028	U-620			
EFINACONAZOLE - JUBLIA								
N 203567	001		10342875	Oct 02, 2034	DP U-2720			
			10478601	Apr 25, 2035	DP U-2721			
ELAGOLIX SODIUM - ORILISSA								
N 210450	001	>A>	10537572	Sep 01, 2036	U-2735			
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR								
N 212614	001	>A>	10022379	Apr 02, 2029	DP U-2732			
		>A>	10258637	Apr 03, 2034	U-2731			
		>A>	10406172	Jun 15, 2030	DP U-2733			
		>A>	6488962	Jun 20, 2020	DP			
		>A>	7407955	May 02, 2025	DS DP			
		>A>	7579449	Nov 05, 2025	DS			
		>A>	7713938	Apr 15, 2027	DS DP			
		>A>	8119648	Aug 12, 2023	U-1652			
		>A>	8178541	Aug 12, 2023	DP U-1652			
		>A>	8551957	Oct 14, 2029	DP U-2730			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	001	>A> 8673927	May 04, 2027			U-1652	
		>A> 8883805	Nov 26, 2025	DP			
		>A> 9155705	May 21, 2030	DP			
		>A> 9173859	May 04, 2027	DP		U-1652	
		>A> 9173859	May 04, 2027	DP		U-2730	
		>A> 9415016	Apr 02, 2029	DP			
		>A> 9949998	Jun 11, 2034			U-2731	
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	002	>A> 10022379	Apr 02, 2029	DP		U-2732	
		>A> 10258637	Apr 03, 2034			U-2731	
		>A> 10406172	Jun 15, 2030	DP		U-2733	
		>A> 6488962	Jun 20, 2020	DP			
		>A> 7407955	May 02, 2025	DS DP			
		>A> 7579449	Nov 05, 2025	DS			
		>A> 7713938	Apr 15, 2027	DS DP			
		>A> 8119648	Aug 12, 2023			U-1652	
		>A> 8178541	Aug 12, 2023	DP		U-1652	
		>A> 8551957	Oct 14, 2029	DP		U-2730	
		>A> 8673927	May 04, 2027			U-1652	
		>A> 8883805	Nov 26, 2025	DP			
		>A> 9155705	May 21, 2030	DP			
		>A> 9173859	May 04, 2027	DP		U-1652	
		>A> 9173859	May 04, 2027	DP		U-2730	
		>A> 9415016	Apr 02, 2029	DP			
		>A> 9949998	Jun 11, 2034			U-2731	
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	003	>A> 10022379	Apr 02, 2029	DP		U-2732	
		>A> 10258637	Apr 03, 2034			U-2731	
		>A> 10406172	Jun 15, 2030	DP		U-2733	
		>A> 6488962	Jun 20, 2020	DP			
		>A> 7407955	May 02, 2025	DS DP			
		>A> 7579449	Nov 05, 2025	DS			
		>A> 7713938	Apr 15, 2027	DS DP			
		>A> 8119648	Aug 12, 2023			U-1652	
		>A> 8178541	Aug 12, 2023	DP		U-1652	
		>A> 8551957	Oct 14, 2029	DP		U-2730	
		>A> 8673927	May 04, 2027			U-1652	
		>A> 8883805	Nov 26, 2025	DP			
		>A> 9155705	May 21, 2030	DP			
		>A> 9173859	May 04, 2027	DP		U-1652	
		>A> 9173859	May 04, 2027	DP		U-2730	
		>A> 9415016	Apr 02, 2029	DP			
		>A> 9949998	Jun 11, 2034			U-2731	
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	004	>A> 10022379	Apr 02, 2029	DP		U-2732	
		>A> 10258637	Apr 03, 2034			U-2731	
		>A> 10406172	Jun 15, 2030	DP		U-2733	
		>A> 6488962	Jun 20, 2020	DP			
		>A> 7407955	May 02, 2025	DS DP			
		>A> 7579449	Nov 05, 2025	DS			
		>A> 7713938	Apr 15, 2027	DS DP			
		>A> 8119648	Aug 12, 2023			U-1652	
		>A> 8178541	Aug 12, 2023	DP		U-1652	
		>A> 8551957	Oct 14, 2029	DP		U-2730	
		>A> 8673927	May 04, 2027			U-1652	
		>A> 8883805	Nov 26, 2025	DP			
		>A> 9155705	May 21, 2030	DP			
		>A> 9173859	May 04, 2027	DP		U-1652	
		>A> 9173859	May 04, 2027	DP		U-2730	
		>A> 9415016	Apr 02, 2029	DP			
		>A> 9949998	Jun 11, 2034			U-2731	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY								
N 208215	001						NPP	Sep 25, 2020
							ODE-284	Sep 28, 2024
							ODE-285	Sep 28, 2024
ENZALUTAMIDE - XTANDI								
N 203415	001	8183274	Aug 24, 2026		U-1281			
		8183274	Aug 24, 2026		U-1588			
		8183274	Aug 24, 2026		U-2345			
		8183274	Aug 24, 2026		U-2708			
		9126941	May 15, 2026		U-1588			
		9126941	May 15, 2026		U-2345			
		9126941	May 15, 2026		U-2708			
EPINEPHRINE - ADRENACLICK								
N 020800	003	10166334	Jan 21, 2025		DP			
EPINEPHRINE - ADRENACLICK								
N 020800	004	10166334	Jan 21, 2025		DP			
ESTRADIOL - IMVEXXY								
N 208564	001	>A> 10537581	Nov 21, 2032		DP U-2316			
		>A> 10537581	Nov 21, 2032		DP U-2317			
ESTRADIOL - IMVEXXY								
N 208564	002	>A> 10537581	Nov 21, 2032		DP U-2316			
		>A> 10537581	Nov 21, 2032		DP U-2317			
ETEPLIRSEN - EXONDYS 51								
N 206488	001	10533174	May 04, 2021		DP			
ETEPLIRSEN - EXONDYS 51								
N 206488	002	10533174	May 04, 2021		DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA								
N 204017	001	>A> 7045145	Mar 14, 2021		DP U-2751		>A> NP	Feb 14, 2023
		>A> 7384650	Mar 14, 2021		DP			
		>A> 8221784	Mar 14, 2021		DP			
		>A> 8221785	Mar 14, 2021		DP			
		>A> 8246978	Aug 26, 2028		DP			
		>A> 8747888	Jul 10, 2028		DP			
		>A> 8883196	Nov 22, 2020		DP U-2751			
		>A> 9050348	Jul 10, 2028		DP			
EXENATIDE SYNTHETIC - BYDUREON								
N 022200	001	>A> 6414126	Oct 04, 2020	DS	DP U-2588			
		>A> 6515117	Oct 04, 2020	DS	DP U-2588			
		>A> 6872700	Jan 14, 2020		U-2588			
		>A> 6872700	Jan 14, 2020		U-2589			
		>A> 6872700	Jan 14, 2020		U-2590			
		>A> 6872700	Jan 14, 2020		U-2591			
		>A> 6936590	Oct 04, 2020		U-2588			
		>A> 7456254	Jun 30, 2025		DP U-2588			
		>A> 7456254	Jun 30, 2025		DP U-2589			
		>A> 7456254	Jun 30, 2025		DP U-2590			
		>A> 7456254	Jun 30, 2025		DP U-2592			
		>A> 7612176	Apr 13, 2025		DP U-2588			
		>A> 7612176	Apr 13, 2025		DP U-2589			
		>A> 7612176	Apr 13, 2025		DP U-2590			
		>A> 7612176	Apr 13, 2025		DP U-2592			
		>A> 8329648	Aug 18, 2026		U-2588			
		>A> 8329648	Aug 18, 2026		U-2589			
		>A> 8329648	Aug 18, 2026		U-2590			
		>A> 8329648	Aug 18, 2026		U-2593			
		>A> 8329648	Aug 18, 2026		U-2594			
		>A> 8329648	Aug 18, 2026		U-2595			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON							
N 022200	001	>A> 8329648	Aug 18, 2026			U-2596	
		>A> 8361972	Mar 21, 2028			U-2588	
		>A> 8431685	Apr 13, 2025	DP		U-2588	
		>A> 8431685	Apr 13, 2025	DP		U-2589	
		>A> 8431685	Apr 13, 2025	DP		U-2590	
		>A> 8431685	Apr 13, 2025	DP		U-2598	
		>A> 8461105	Apr 13, 2025	DP		U-2588	
		>A> 8461105	Apr 13, 2025	DP		U-2589	
		>A> 8461105	Apr 13, 2025	DP		U-2590	
		>A> 8461105	Apr 13, 2025	DP		U-2598	
		>A> 8501698	Jun 20, 2027	DP		U-2588	
		>A> 8906851	Aug 18, 2026			U-2588	
		>A> 8906851	Aug 18, 2026			U-2589	
		>A> 8906851	Aug 18, 2026			U-2590	
		>A> 8906851	Aug 18, 2026			U-2593	
		>A> 9198925	Oct 04, 2020			U-2588	
		>A> 9238076	Apr 15, 2024	DP		U-2588	
		>A> 9238076	Apr 15, 2024	DP		U-2589	
		>A> 9238076	Apr 15, 2024	DP		U-2590	
		>A> 9238076	Apr 15, 2024	DP		U-2599	
		>A> 9884092	Aug 18, 2026			U-2588	
		>A> 9884092	Aug 18, 2026			U-2589	
		>A> 9884092	Aug 18, 2026			U-2590	
		>A> 9884092	Aug 18, 2026			U-2593	
		>A> 9884092	Aug 18, 2026			U-2594	
		>A> 9884092	Aug 18, 2026			U-2595	
		>A> 9884092	Aug 18, 2026			U-2596	
EXENATIDE SYNTHETIC - BYDUREON PEN							
N 022200	002	>A> 6414126	Oct 04, 2020	DS DP		U-2588	
		>A> 6515117	Oct 04, 2020	DS DP		U-2588	
		>A> 6872700	Jan 14, 2020			U-2588	
		>A> 6872700	Jan 14, 2020			U-2589	
		>A> 6872700	Jan 14, 2020			U-2590	
		>A> 6872700	Jan 14, 2020			U-2591	
		>A> 6936590	Oct 04, 2020			U-2588	
		>A> 7456254	Jun 30, 2025	DP		U-2588	
		>A> 7456254	Jun 30, 2025	DP		U-2589	
		>A> 7456254	Jun 30, 2025	DP		U-2590	
		>A> 7456254	Jun 30, 2025	DP		U-2592	
		>A> 7612176	Apr 13, 2025	DP		U-2588	
		>A> 7612176	Apr 13, 2025	DP		U-2589	
		>A> 7612176	Apr 13, 2025	DP		U-2590	
		>A> 7612176	Apr 13, 2025	DP		U-2592	
		>A> 8329648	Aug 18, 2026			U-2588	
		>A> 8329648	Aug 18, 2026			U-2589	
		>A> 8329648	Aug 18, 2026			U-2590	
		>A> 8329648	Aug 18, 2026			U-2593	
		>A> 8329648	Aug 18, 2026			U-2594	
		>A> 8329648	Aug 18, 2026			U-2595	
		>A> 8329648	Aug 18, 2026			U-2596	
		>A> 8361972	Mar 21, 2028			U-2588	
		>A> 8431685	Apr 13, 2025	DP		U-2588	
		>A> 8431685	Apr 13, 2025	DP		U-2589	
		>A> 8431685	Apr 13, 2025	DP		U-2590	
		>A> 8431685	Apr 13, 2025	DP		U-2598	
		>A> 8461105	Apr 13, 2025	DP		U-2588	
		>A> 8461105	Apr 13, 2025	DP		U-2589	
		>A> 8461105	Apr 13, 2025	DP		U-2590	
		>A> 8461105	Apr 13, 2025	DP		U-2598	
		>A> 8501698	Jun 20, 2027	DP		U-2588	
		>A> 8906851	Aug 18, 2026			U-2588	
		>A> 8906851	Aug 18, 2026			U-2589	
		>A> 8906851	Aug 18, 2026			U-2590	
		>A> 8906851	Aug 18, 2026			U-2593	
		>A> 9198925	Oct 04, 2020			U-2588	
		>A> 9238076	Apr 15, 2024	DP		U-2588	
		>A> 9238076	Apr 15, 2024	DP		U-2589	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON PEN							
N 022200 002	>A>	9238076	Apr 15, 2024	DP U-2590			
	>A>	9238076	Apr 15, 2024	DP U-2599			
	>A>	9884092	Aug 18, 2026	U-2588			
	>A>	9884092	Aug 18, 2026	U-2589			
	>A>	9884092	Aug 18, 2026	U-2590			
	>A>	9884092	Aug 18, 2026	U-2593			
	>A>	9884092	Aug 18, 2026	U-2594			
	>A>	9884092	Aug 18, 2026	U-2595			
	>A>	9884092	Aug 18, 2026	U-2596			
FERRIC CARBOXYMALTOSE - INJECTAFER							
N 203565 001		10519252	Oct 20, 2023	DS U-2709			
		10519252	Oct 20, 2023	DS U-2710			
		10519252	Oct 20, 2023	DS U-2711			
		10519252	Oct 20, 2023	DS U-2712			
FERRIC CITRATE - AURYXIA							
N 205874 001		5753706	Feb 03, 2021	DP U-1577			
FERRIC DERISOMALTOSE - MONOFERRIC							
N 208171 001	>A>	10414831	Mar 25, 2029	DS DP			
	>A>	8815301	Aug 14, 2029	DS DP U-2734			
FIDAXOMICIN - DIFICID							
N 201699 001	>A>	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	>A>	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	>A>	7906489*PED	Sep 04, 2027				
	>A>	8859510	Jul 31, 2027	U-2741			
	>A>	8859510	Jul 31, 2027	U-319			
	>A>	8859510*PED	Jan 31, 2028				
FIDAXOMICIN - DIFICID							
N 213138 001	>A>	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	>A>	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	>A>	7863249	Jul 31, 2027	DP			
	>A>	7863249*PED	Jan 31, 2028				
	>A>	7906489	Mar 04, 2027	U-2741			
	>A>	7906489*PED	Sep 04, 2027				
	>A>	8586551	Jul 23, 2023	DS DP			
	>A>	8586551*PED	Jan 23, 2024				
	>A>	8859510	Jul 31, 2027	U-2741			
	>A>	8859510*PED	Jan 31, 2028				
	>A>	9808530	May 28, 2034	DP			
	>A>	9808530*PED	Nov 28, 2034				
FINGOLIMOD HYDROCHLORIDE - GILENYA							
N 022527 001		10543179	Dec 25, 2027	U-2719			
GLUCAGON - GVOKE PFS							
N 212097 001	>A>	9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE PFS							
N 212097 002	>A>	9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE HYPOPEN							
N 212097 003	>A>	9649364	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE HYPOPEN							
N 212097 004	>A>	9649364	Apr 22, 2036	DP U-2742			
GLYCOPYRRONIUM TOSYLATE - QBREXZA							
N 210361 001	>A>	10543192	Feb 28, 2033	DP			
	>A>	10548875	Feb 28, 2033	DS DP U-2398			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GOLODIRSEN - VYONDYS 53							
N 211970 001		10533174	May 04, 2021	DP		ODE-280	Dec 12, 2026
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT							
N 022555 001	>A>	10556010	Dec 19, 2036	U-2250			
HYDROGEN PEROXIDE - ESKATA							
N 209305 001		10493103	Apr 21, 2035	DP			
ICOSAPENT ETHYL - VASCEPA							
N 202057 001	>A>	10555924	Jun 28, 2033	U-2743			
	>A>	10555925	Jun 28, 2033	U-2744			
ICOSAPENT ETHYL - VASCEPA							
N 202057 002	>A>	10555924	Jun 28, 2033	U-2743			
	>A>	10555925	Jun 28, 2033	U-2744			
LACTITOL - PIZENSY							
N 211281 001					>A>	NCE	Feb 12, 2025
LASMIDITAN SUCCINATE - REYVOW							
N 211280 001						NCE	Jan 31, 2025
LASMIDITAN SUCCINATE - REYVOW							
N 211280 002						NCE	Jan 31, 2025
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 001	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 002	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 003	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 004	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 005	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 006	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 007	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 008	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 009	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 010	>A>	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL							
N 206977 011	>A>	10537538	Feb 28, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT-SOL								
N 206977	012	>A>	10537538	Feb 28, 2037	DP			
LUMATEPERONE TOSYLATE - CAPLYTA								
N 209500	001		10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
			7183282	Jun 15, 2020	DS DP			
			8598119	Dec 28, 2029	U-543			
			8648077	Dec 01, 2029	DS DP			
			9199995	Mar 12, 2029	U-2713			
			9586960	Mar 12, 2029	DS DP			
			9616061	May 27, 2029	DP			
			9956227	Dec 03, 2034	U-2714			
			RE39680	Jun 15, 2020	DS DP U-543			
MELOXICAM - ANJESO								
N 210583	001	>A>	10463673	Feb 24, 2024	DP U-2750		>A> NP	Feb 20, 2023
		>A>	10471067	Feb 24, 2024	DP U-2750			
		>A>	8512727	Dec 25, 2022	DP U-2750			
		>A>	9974746	May 26, 2030	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR								
N 212038	001	>A>	10568841	Oct 30, 2035	DP U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR								
N 212038	002	>A>	10568841	Oct 30, 2035	DP U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR								
N 212038	003	>A>	10568841	Oct 30, 2035	DP U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR								
N 212038	004	>A>	10568841	Oct 30, 2035	DP U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR								
N 212038	005	>A>	10568841	Oct 30, 2035	DP U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR								
N 212038	006	>A>	10568841	Oct 30, 2035	DP U-2357			
MICAFUNGIN SODIUM - MYCAMINE								
N 021506	002						I-821	Dec 20, 2022
							PED	Jun 20, 2023
MICAFUNGIN SODIUM - MYCAMINE								
N 021506	003						I-821	Dec 20, 2022
							PED	Jun 20, 2023
MIGALASTAT HYDROCHLORIDE - GALAFOLD								
N 208623	001		10525045	Apr 28, 2028	U-2371			
MINOCYCLINE HYDROCHLORIDE - AMZEEQ								
N 212379	001		10517882	Oct 01, 2030	U-2647			
NERATINIB MALEATE - NERLYNX								
N 208051	001						>A> I-823	Feb 25, 2023
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO								
N 205718	001	>A>	6297375	Mar 17, 2023	DS			
OCTREOTIDE ACETATE - BYNFEZIA PEN								
N 213224	001		10342850	May 15, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-283	Dec 27, 2026
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	9566276	Mar 12, 2024	U-2716			
OLAPARIB - LYNPARZA						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-283	Dec 27, 2026
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	9566276	Mar 12, 2024	U-2716			
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 001					M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 002					M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 003					M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021246 001					M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021246 002					M-251	Aug 02, 2022
PEMETREXED - PEMFEXY						
N 209472 001	7772209	May 24, 2022	U-2728			
	7772209	May 24, 2022	U-2729			
POMALIDOMIDE - POMALYST						
N 204026 001	>A> 10555939	May 19, 2030	DP			
POMALIDOMIDE - POMALYST						
N 204026 002	>A> 10555939	May 19, 2030	DP			
POMALIDOMIDE - POMALYST						
N 204026 003	>A> 10555939	May 19, 2030	DP			
POMALIDOMIDE - POMALYST						
N 204026 004	>A> 10555939	May 19, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REVEFENACIN - YUPELRI							
N 210598 001		10550081	Jul 14, 2030	DS			
RIMEGEPANT SULFATE - NURTEC ODT							
N 212728 001						>A> NCE	Feb 27, 2025
RIVAROXABAN - XARELTO							
N 022406 004						>A> I-824	Oct 11, 2021
SELINEXOR - XPOVIO							
N 212306 001		10519139	Aug 14, 2035	DS DP U-2584			
	>A>	10544108	Jul 26, 2032	U-2584			
SEMAGLUTIDE - OZEMPIC							
N 209637 001						I-822	Jan 16, 2023
SEMAGLUTIDE - OZEMPIC							
N 209637 002						I-822	Jan 16, 2023
SEMAGLUTIDE - RYBELSUS							
N 213051 001						M-252	Jan 16, 2023
SEMAGLUTIDE - RYBELSUS							
N 213051 002						M-252	Jan 16, 2023
SEMAGLUTIDE - RYBELSUS							
N 213051 003						M-252	Jan 16, 2023
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI							
N 211230 001		10512609	Sep 05, 2037	U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI							
N 211230 002		10512609	Sep 05, 2037	U-2548			
SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH							
N 208223 001		10537554	Jan 29, 2036	U-72			
SUVOREXANT - BELSOMRA							
N 204569 001						M-253	Jan 29, 2023
SUVOREXANT - BELSOMRA							
N 204569 002						M-253	Jan 29, 2023
SUVOREXANT - BELSOMRA							
N 204569 003						M-253	Jan 29, 2023
SUVOREXANT - BELSOMRA							
N 204569 004						M-253	Jan 29, 2023
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK							
N 211723 001	>A>	10155002	Apr 13, 2032	U-2736		NCE	Jan 23, 2025
	>A>	10245269	Apr 11, 2033	U-2737			
	>A>	10369155	Oct 16, 2035	U-2736			
	>A>	10420775	Apr 13, 2032	U-2736			
	>A>	8410088	Apr 13, 2032	DS DP			
	>A>	9090562	Apr 13, 2032	DS DP			
	>A>	9394283	Apr 11, 2033	DS DP			
	>A>	9522152	Apr 13, 2032	U-2738			
	>A>	9549931	Apr 13, 2032	U-2736			
	>A>	9688665	Aug 22, 2034	U-2736			
	>A>	9855275	Apr 13, 2032	U-2736			
	>A>	9872862	Apr 11, 2033	U-2738			
	>A>	9889138	Oct 16, 2035	U-2736			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK							
N 211723	001	>A> 10155002	Apr 13, 2032	U-2736		NCE	Jan 23, 2025
		>A> 10245269	Apr 11, 2033	U-2737			
		>A> 10369155	Oct 16, 2035	U-2736			
		>A> 10420775	Apr 13, 2032	U-2736			
		>A> 8410088	Apr 13, 2032	DS DP			
		>A> 9090562	Apr 13, 2032	DS DP			
		>A> 9394283	Apr 11, 2033	DS DP			
		>A> 9522152	Apr 13, 2032	U-2738			
		>A> 9549931	Apr 13, 2032	U-2736			
		>A> 9688665	Aug 22, 2034	U-2736			
		>A> 9855275	Apr 13, 2032	U-2736			
		>A> 9872862	Apr 11, 2033	U-2738			
		>A> 9889138	Oct 16, 2035	U-2736			
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205435	001	>A> 7816379	Apr 20, 2026	DS DP U-2507			
		>A> 7816379	Apr 20, 2026	DS DP U-282			
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205436	001	>A> 7816379	Apr 20, 2026	DS DP U-2507			
		>A> 7816379	Apr 20, 2026	DS DP U-282			
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY							
N 208464	001					>A> M-255	Feb 04, 2023
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089	001	>A> 10543219	Apr 12, 2030	U-2506			
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089	002	>A> 10543219	Apr 12, 2030	U-2506			
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089	003	>A> 10543219	Apr 12, 2030	U-2506			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	001	8747897	Aug 11, 2031	DP U-2724			
		8747897	Aug 11, 2031	DP U-2725			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	002	8747897	Aug 11, 2031	DP U-2724			
		8747897	Aug 11, 2031	DP U-2725			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	003	8747897	Aug 11, 2031	DP U-2724			
		8747897	Aug 11, 2031	DP U-2725			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	004	8747897	Aug 11, 2031	DP U-2724			
		8747897	Aug 11, 2031	DP U-2725			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	005	8747897	Aug 11, 2031	DP U-2724			
		8747897	Aug 11, 2031	DP U-2725			
TRIPTORELIN PAMOATE - TRELSTAR							
N 022437	001	>A> 10166181	Jun 30, 2029	DP			
TRIPTORELIN PAMOATE - TRIPTODUR KIT							
N 208956	001	10166181	Jun 30, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2020

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UBROGEPANT - UBRELVY							
N 211765 001		10117836	Jan 30, 2035	DP			
		8754096	Jul 19, 2032	DS DP U-2717			
		8912210	Nov 10, 2031	DS DP			
		9499545	Nov 10, 2031	DS DP U-2718			
		9833448	Nov 10, 2031	U-2718			
UBROGEPANT - UBRELVY							
N 211765 002		10117836	Jan 30, 2035	DP			
		8754096	Jul 19, 2032	DS DP U-2717			
		8912210	Nov 10, 2031	DS DP			
		9499545	Nov 10, 2031	DS DP U-2718			
		9833448	Nov 10, 2031	U-2718			
UPADACITINIB - RINVOQ							
N 211675 001		10519164	Oct 17, 2036	DP			
VENETOCLAX - VENCLEXTA							
N 208573 001	>A>	8722657	Jan 29, 2032	DS			
VENETOCLAX - VENCLEXTA							
N 208573 002	>A>	8722657	Jan 29, 2032	DS			
VENETOCLAX - VENCLEXTA							
N 208573 003	>A>	8722657	Jan 29, 2032	DS			
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567 001		7834020	Jun 05, 2022	DS DP U-839		>A> M-254	Jan 31, 2023
		7834020*PED	Dec 05, 2022			>A> PED	Jul 31, 2023
		8193195	Jun 05, 2022	U-839			
		8193195*PED	Dec 05, 2022				
		8236804	Jun 05, 2022	U-839			
		8236804*PED	Dec 05, 2022				
		8673921	Jun 05, 2022	DS DP			
		8673921*PED	Dec 05, 2022				
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567 002		7834020	Jun 05, 2022	DS DP U-839		>A> M-254	Jan 31, 2023
		7834020*PED	Dec 05, 2022			>A> PED	Jul 31, 2023
		8193195	Jun 05, 2022	U-839			
		8193195*PED	Dec 05, 2022				
		8236804	Jun 05, 2022	U-839			
		8236804*PED	Dec 05, 2022				
		8673921	Jun 05, 2022	DS DP			
		8673921*PED	Dec 05, 2022				
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567 003		7834020	Jun 05, 2022	DS DP U-839		>A> M-254	Jan 31, 2023
		7834020*PED	Dec 05, 2022			>A> PED	Jul 31, 2023
		8193195	Jun 05, 2022	U-839			
		8193195*PED	Dec 05, 2022				
		8236804	Jun 05, 2022	U-839			
		8236804*PED	Dec 05, 2022				
		8673921	Jun 05, 2022	DS DP			
		8673921*PED	Dec 05, 2022				
VOXELOTOR - OXBRYTA							
N 213137 001		10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
		10034879	Dec 28, 2032	DS DP			
		10493035	Oct 12, 2037	DP			
		9018210	Dec 28, 2032	DS DP			
		9248199	Jan 29, 2034	U-2676			
		9248199	Jan 29, 2034	U-2715			
		9447071	Feb 06, 2035	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm